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Summary 
Tremendous progress in treatment and outcomes has been achieved across the spectrum of 
haematologic malignancies over the last two decades.  While cure rates for aggressive 
malignancies have risen, nowhere has progress been more impactful than in the management of 
typically incurable forms of haematologic cancer.  Population-based data have demonstrated 
substantial improvement in five-year survival rates for chronic myelogenous and chronic 
lymphocytic leukaemia, indolent B-cell lymphomas, diffuse large B-cell lymphoma, and multiple 
myeloma.  This has resulted in large part from paradigm shifting changes in disease management 
strategies in these malignancies.  Several haematologic malignancies are now experienced by 
patients as chronic illnesses.  In this Commission, an international panel of clinicians, clinical 
investigators, methodologists, regulators and patient advocates representing a broad range of 
academic and clinical cancer expertise examine adverse events (AEs) in this new landscape of 
haematologic malignancies.  This international collaborative effort aims to improve toxicity 
assessment in haematologic malignancies and addresses changes to the current process of AE 
assessment, incorporating patient reported outcomes, issues in stem cell transplantation, toxicities 
in survivorship, regulatory approval challenges, toxicity reporting in the real world, and financial 
burden of contemporary therapies, all of which present new challenges in the current treatment era 
world-wide. 
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Introduction:  Haematologic Malignancies and Their Therapies Have Changed 
The haematologic malignancies have been the model for radiation therapy, chemotherapy, 
immunotherapy, immunomodulators, adoptive t-cell, oncolytic virus, interferons, cytokines, 
cancer vaccines, and chimeric antigen receptor T cell therapies (Table 1, Table 2). These 
modalities are incorporated into different disease types and result in a variety of adverse events 
(AEs), some well characterized and others less understood.   New treatments have dramatically 
changed the natural history of many of these diseases.  The paradigm is now chronic therapy for 
years or indefinitely with an expectation of normal life expectancy relative to the normal 
population in some haematologic malignancies diseases.  Along with this shift, the patient 
experience of treatment toxicity has changed substantially.   
Lymphoma treatment is one demonstration of changes in paradigms of therapy and the 
rising use of newer, chronically administered agents in haematologic malignancies (Figure 1.)  In 
Hodgkin lymphoma (HL), limited stage disease was previously managed with high dose radiation 
therapy (RT) and advanced disease with combination chemotherapy and RT.(1, 2) The late term 
toxicity of these treatment approaches – including secondary malignancies, heart disease, and 
pulmonary disease – resulted in more treatment–related deaths from complications of survival than 
deaths from disease.  HL is now managed with de-escalation approaches where possible with either 
three cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) in positron emission 
tomography (PET) negative patients or 2 cycles of ABVD followed by 20 Gy radiation therapy.(3, 
4)  The addition of rituximab to chemotherapy, immunochemotherapy, improved overall survival 
in diffuse large B-cell lymphoma(5-7) and advanced stage follicular lymphoma,(8, 9) and 
introduced short and later term toxicities of monoclonal antibody therapy, such as infusion 
reactions and polyoma virus reactivation(10).  
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Indolent forms of lymphoproliferative disorders such as CLL and follicular lymphoma (FL) 
have long been approached as chronic illnesses, but the availability of novel therapeutics has led 
to a shift in disease management strategies. Whereas historically treatment was largely episodic 
and finite – a set number of cycles of chemotherapy – many patients now receive chronic oral 
therapy for relapsed disease(11) or even first-line therapy.(12) Ibrutinib, approved by the FDA as 
first-line therapy of CLL, has a median progression-free survival in excess of three years, and both 
idelalisib(13) and venetoclax(14) – each approved for relapsed CLL – share the model of 
continuous oral therapy, in which treatments are administered until progression or intolerance. 
Follicular lymphoma is also shifting towards a chronic-therapy model, either with maintenance 
intravenous therapy with monoclonal antibodies (rituximab or obinutuzumab(15, 16)), or with 
chronic oral therapy.   Idelalisib is FDA-approved in the US for relapsed FL(17), ibrutinib for 
Waldenström’s macroglobulinemia(18), and a host of other oral agents are in active development 
internationally using this chronic-oral-therapy approach.  
In multiple myeloma, the median survival prior to 1997 was 2.5 years which had improved 
to 4 years by 2008 with the increased use of high dose therapy and the addition of thalidomide, 
bortezomib, and lenalidomide along with improved supportive care measures.(19)  In 2013, the 
USA Food and Drug Administration approved pomalidomide and carfilzomib.  In 2015, four 
additional drugs were approved in the US: panobinostat, ixazomib, elotuzumab, and daratumumab.  
The standard of care is now triplet therapy with the advent of new therapies (Table 3).(20-22) 
Venetoclax has now been reported as a promising targeted therapy for relapsed/refractory t(11;14) 
multiple myeloma.(23)   
Perhaps no diseases better exemplifies this paradigm shift than chronic myelogenous 
leukaemia (CML). In 1983, the mainstays of treatment in chronic myelogenous leukaemia were 
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busulfan and hydroxyurea followed by recombinant interferon alfa in combination with cytosine 
arabinoside, and allogeneic stem cell transplantation.(24)  CML is now treated almost exclusively 
with oral tyrosine kinases targeting BCR-ABL. The approved agents of this class, initially 
imatinib, has now been expanded to include dasatinib, nilotinib, bosutinib, radotinib and ponatinib 
and these continuously administered agents have resulted in life expectancy that approximates that 
of the age-matched normal population.(25)  Along with improved survival, these agents introduced 
a host of novel toxicities and elucidated the importance of compliance with oral therapies.  Rates 
of less than 90% compliance with imatinib are associated with a 28.4% probability of major 
molecular response (MMR) versus 94.5% if greater than 90%.  Less than 80% adherence to 
imatinib yields a very low likelihood of molecular response.  Adherence and the achievement of 
MMR are the only independent predictors for outcome.(26) At the same time, only 32.7% of CML 
patients have shown to be highly adherent to therapy. Specific CML-related side effects had a 
significant prognostic influence on the level of intentional non-adherence, and those patients 
whose side effects were well-managed were more likely to belong to the highly adherent 
group.(77) To further complicate the issue of toxicity, AEs may also occur when patients withdraw 
from the tyrosine kinase inhibitors.(27) 
Treatment of myeloid malignancies beyond CML has also evolved substantially. 
Lenalidomide improved the outcomes of patients with myelodysplastic syndromes (MDS) and the 
cytogenetic abnormality del(5q), resulting in transfusion independence and improved quality of 
life.(28) Patients with higher risk MDS, who historically lacked effective treatment options, can 
now be maintained, at times for years with hypomethylating agents, allowing some patients to live 
with MDS as a chronic illness.(29)  In the acute leukaemias, targeted therapies are being explored 
for use in addition to conventional cytotoxic rather in its place, with the notable exception of acute 
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promyelocytic leukaemia (APL) where targeted therapy with all-trans retinoic acid (ATRA) and 
arsenic trioxide are capable of curing a high proportion of patients without the use of any cytotoxic 
chemotherapy. In acute myeloid leukaemia (AML) after approximately four decades, the US FDA 
for the first time approved three drugs in 2017: midostaurin, a FLT3 inhibitor for FLT3 mutated 
AML(30), enasidenib, an IDH2 inhibitor for relapsed/refractory IDH2 mutant AML(31), and 
CPX-351, a liposomal formulation of daunorubicin and cytarabine which demonstrated a survival 
benefit and better tolerability in secondary AML(32).  
The landscape of haematologic malignancies has been changed not only by continuously 
administered targeted therapies but also by advances in immunotherapy and cellular therapies. 
Bispecific antibodies such as blinatumomab in ALL(33), checkpoint blockade inhibitors such as 
pembrolizumab and nivolumab in HL(34, 35), and the advent of CAR-T cells(36), approved in 
2017 in the US for the treatment of relapsed lymphoma, have also brought a dramatic shift in 
therapy of some diseases, as well as new risk and new categories of AEs. 
The result of paradigm shifts across haematologic malignancies is that growing numbers 
of patients are living with the challenge of managing not just their haematologic malignancy, but 
also managing the chronic therapy for their illnesses in some cases, and new types of toxicities in 
others. Changing side effects of therapy, psychosocial impact on the patient and treatment 
adherence are increasingly relevant. Financial burdens of these treatments include not only drug 
costs, but also physician outpatient visits and hospitalizations. Patients and healthcare providers 
often find themselves poorly equipped to manage these complex challenges. 
In this commission, an international expert panel of physicians, clinical investigators, 
researchers, methodologists, regulators and patient advocates collaborated to identify and begin to 
address challenges in AE assessment in the modern era of haematologic malignancies.   
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Subsection I: Current Processes in Adverse Event Assessment: Strengths & Shortcomings 
There are numerous challenges and potential solutions to improving AE assessment in 
haematology, and inherent to these are an understanding of the strengths and shortcomings of our 
current approach to toxicity assessment.  The new therapies that have changed the face of 
haematologic malignancies bring with them a different range of toxicities, including an increasing 
number of long-term symptomatic side-effects that challenge our traditional approaches to collect 
and communicate drug-related AEs.  This subsection will address our current processes for 
defining and analyzing AEs, and then begin to introduce issues and solutions in how we capture 
and analyse toxicity data on clinical trials, including how optimizing AE assessment may influence 
the drug development process.  The section will conclude with issues pertaining to AE assessment 
that are unique to haematology.     
Current processes for standardization of AE terminology 
The initial steps in development of new agents require harmonized systems for patient 
safety monitoring that can be utilized internationally.  The National Cancer Institute’s Common 
Terminology Criteria for Adverse Events (NCI CTCAE)(37), recently published in its fifth 
version, is one such system.(38)  Although the NCI CTCAE version 5.0 has international 
acceptance for establishing severity-based AE grading, other international systems use MedDRA 
(Medical Dictionary for Regulatory Activities) terminology to describe AEs. The purpose of the 
CTCAE is to provide standards for the description and exchange of safety information of new 
cancer therapies and treatment modalities in haematology and oncology.  It is used to define 
protocol parameters, such as maximum tolerated dose (MTD), dose limiting toxicity (DLT), and 
provide eligibility parameters and guidance for dose modification.  In 1982, the Cancer Therapy 
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Evaluation Program (CTEP), National Cancer Institute (NCI) developed its first version of the 
Common Toxicity Criteria (CTC). The CTC was used in adverse drug experience reporting, study 
AE summaries, Investigational New Drug (IND) reports to the FDA, and publications.  The 
original version of the CTC included 49 AE terms grouped in 18 categories, each with criteria for 
grading the severity of the AE.  In 1998, the CTC v2.0, with 24 Categories and over 250 AEs, was 
published.  Appendixes containing the Radiation Therapy Oncology Group (RTOG)/European 
Organization for Research and Treatment of Cancer (EORTC) Late Radiation Morbidity Scoring 
Scheme and the BMT Complex/Multi-Component Event Scheme were added.  The NCI CTC v2.0 
became the worldwide standard dictionary for reporting acute AEs in cancer clinical trials.  
CTCAE v3.0 was the first uniform and comprehensive dictionary of AE grading criteria available 
for use by all modalities used in the treatment of cancer, and included criteria relevant to surgical, 
radiation and pediatric-based clinical trials.  The adoption of MedDRA® terminology by the ICH 
(International Conference on Harmonization), NCI, industry, and regulatory bodies provided the 
impetus for NCI to undertake a redesign of CTCAE in 2008 to be harmonized with MedDRA.  In 
CTCAE version 4.0, standards included AE terms that correspond to MedDRA Lowest Level 
Terms (LLTs) that are organized in MedDRA System Organ Class (SOC) groupings, with a 
severity grading scale.  Finally, version 5.0 of the CTCAE will be published in 2017 and includes 
the addition of new AE terms and revision of existing grading scales. CTCAE version 5.0 has 837 
terms, updated grading information, and a more comprehensive index. 
In addition to standardizing the terminology, it is useful to define adverse effects in relation 
to timing of drug exposure.  Table 4 provides definitions for acute, chronic, cumulative and late 
effects. Acute effects describe AEs that develop within a short, defined timeframe; they can be 
transient, reversible or persistent.  Chronic effects are those AEs that develop over time to be a 
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persistent and unremitting, or intermittent and recurring, series of events, extending past a defined 
interval such as the first cycle of therapy.  In contrast, cumulative AEs develop and increase with 
repeated exposures to drug.  Finally, late effects are AEs that result in subclinical or asymptomatic 
physiologic changes that do not result in immediate, intermittent, or short-term adverse clinical 
events, but rather may manifest over an extended timeframe.   
Improving AE analysis: aggregated safety analysis, graphic readouts and depicting time profile 
of AEs   
Precise, consensus definitions of AEs and their severity are as important as a consensus 
method of analyzing and describing AE data.  Current methods of AE analysis fall short in 
describing toxicities of modern therapies for haematologic malignancies.  Typically, when AE data 
are presented in a clinical trial report, they are in the form of a summary table of the high-grade 
toxicity experienced by any patient over the course of the trial.  This provides an efficient and 
effective way to rapidly assess safety by displaying the number and percentage of high grade 
events.  However, these tables provide no information on the trajectory of the AEs, their onset, 
progression or cumulative effects which may substantially affect tolerability, as will be described 
further in the subsequent subsection.  Longitudinal graphs of the prevalence of specific AEs would 
provide more information about how the AEs arise and whether the effect becomes cumulative, 
and resolves with supportive care, dose modification or cycle/course of therapy (Figure 2-4).   
The NCI Web Reporting System is one tool which facilitates graphical outputs of AE 
information.  One such output is shown in Figure 2 which represents a more user friendly visual 
output of AE data than a conventional maximum grade table.  Figure 1 illustrates both the 
advantages of following toxicity over time and the limitations in collecting data on chronic toxicity 
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in early phase I and II trials.  Although early in the courses of therapy there is an apparent decrease 
in severe toxicity, assessment in later courses is limited because of patient attrition from the trial.   
Other types of tools, such as the Toxicity over Time (ToxT) package, produce analytic and 
graphical outputs that include a depiction of the time profile of AES as well as assessment of the 
burden of chronic low grade AEs.(39) The ToxT performs longitudinal analyses to depict 
timeframe of AEs in a variety of ways, including bar charts depicting incidence and grade of AEs 
by cycle, stream plots showing grade AE by cycle, time to event analyses (Figure 3), as well as 
an area under the curve (Figure 4).  An area under the curve approach is particularly relevant to 
capturing the impact of chronic low grade toxicity.  A patient with a continuous low grade toxicity, 
such as continuous grade 2 diarrhea (4-6 stools above baseline daily), should be accounted for as 
their experience is potentially more substantial than a short-lived, isolated grade 3 toxicity.  AUC 
analysis provides this information in numerical and graphical form, and is depictured in both 
Figure 1B from the NCI Web Reporting System and Figure 3 from the ToxT.  Current methods do 
not sufficiently capture cumulative dose of agents by using AE data from multiple cycles.  These 
approaches have not yet been integrated prospectively into phase 1 designs, but may help identify 
more tolerable dosing approaches.   
Chronic low-grade toxicities can limit the long-term delivery of therapy; a highly effective 
approach to the evaluation of most of these AEs is the use of Patient Reported Outcomes (PROs) 
described in greater detail in Subsection II. Other potential approaches to improving toxicity 
analysis may include pre-programmed algorithms that identify patterns of combined toxicities that 
portend added risk for severe events or development of syndromes, e.g. cerebrovascular events, 
haemolytic uremic syndrome, cardiovascular events.   
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Challenges in dose and schedule determination in early phase haematology trials  
Understanding AE definitions and modes of analysis, we will now address AE assessment 
in drug development.  Stepwise approaches streamline drug development and lead to the most 
efficient evaluation of new treatments for haematology patients.  Throughout this development 
process, dose determination is driven by the accumulation of AEs that are used in aggregate to 
identify the recommended dose and schedule for later phase investigations.  Given that many 
therapeutics in haematological malignancies are now administered over prolonged periods or 
chronically until disease progression, however, clinical trial designs need to address dose 
determination and refinement beyond the phase 1 dose escalation.  The phase 1 dose escalation 
study is commonly used for the determination of the dose, schedule and sequence of new drugs in 
oncology and other disciplines.  DLT definitions are generally based on single cycle, acute AEs 
that are of sufficient severity that dosing cannot be continued at the current dose level.  During the 
phase 1 study the safety of a drug is often evaluated during the fixed time interval of one cycle.  
When developing non-cytotoxic, continuously or chronically administered therapies, the 
relationship between dose-response and toxicity may not be well understood, and evaluating 
tolerability in such a short window may not be possible(40) (see below and Subsection II for further 
discussion on tolerability).  Molecularly-targeted and immune-oncology drugs may not have doses 
and schedules determined during the first cycle of therapy, leading to inexact descriptions of DLTs.  
This hampers establishing the MTD and the recommended phase 2 dose (RP2D) once dose 
escalation is completed(41).   
One way to address this issue is to lengthen the DLT observation window to two or three 
cycles prior to establishing the recommended phase 2 dose and schedule.  Alternatively, expansion 
cohorts may further characterize safety and tolerability of a treatment which may lead to further 
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dose and schedule refinement.  Phase 2 trials evaluating safety, tolerability and activity or efficacy 
of molecularly-targeted or immune-oncology drugs may inform dose/schedule refinement.  
Improving the design of these trials to efficiently determine the dose and schedule to move forward 
is critically important.  
The current short observation window for DLT in phase 1 clinical trials does not permit 
evaluation of lower grade, chronic toxicities which often leading to dose modification or delay in 
later cycles and impact tolerability, thus compromising effective dose delivery and in some 
instances efficacy, altering the benefit-risk assessment of therapy over time.  The impact of these 
low-grade toxicities on quality of life in patients with advanced disease may become intolerable 
with chronic administration, and are often missed in the standard phase 1 trial DLT evaluation 
window(42, 43).  Inclusion late or delayed AEs to determine RP2D is not standardized.  Further 
study of DLTs that occur outside of AE narrowly-specified time frame is required.  
  One adaptive design that may assist in the evaluation of chronic low grade AEs is the 
mTPI design(44) that uses all AEs data prior to dose escalation or de-escalation.  It may require 
further modification as it also evaluates DLT in only the first cycle of treatment but could be 
changed to include a total of two or three cycles prior to selection of the recommended dose and 
schedule.  Its advantage is each AE regardless of grade is used for dose selection rather than only 
the AEs in one cycle of therapy using 3-6 patients.  The larger sample size increases the confidence 
that the RP2D determination will establish a safe, tolerable dose and schedule of a new drug that 
is clinically relevant particularly when AEs occur outside of the DLT window.  However, a 
qualitative judgment analysis of the impact of chronic low grade AEs may be needed to evaluate 
the impact of therapy.  
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Challenges to the drug development process posed by chronic, cumulative and late effects 
Given that the occurrence of chronic, cumulative and late effects are inherent to many 
modern therapies for haematologic cancers, longer-term follow-up of patients in both early and 
later phase trials may be needed to capture the relevant AE profile.  One example of the need for 
novel trial designs and longer DLT observation windows came from the analysis of 54 phase I 
trials of molecularly targeted agents.(41)  Almost a quarter of the patients treated (n=599) who 
developed grade 3 or higher AEs, had their DLT observed after their first cycle of treatment.  Of 
the 2084 patients reviewed in this analysis, grade 2 AEs such as diarrhea, fatigue and neutropenia, 
were observed at the highest frequency in treatment cycles 3 to 6, and not during cycle 1.  Another 
example came from a pooled analysis of 576 patients receiving nivolumab for advanced 
melanoma(45). AEs of any grade occurred any time between 5 weeks for skin toxicities to 15 
weeks for renal toxicities for median time to onset.  
 A greater challenge is capturing the contribution of toxicity attributable to a novel agent 
that occurs late in the overall therapeutic course.  In classical Hodgkin lymphoma, where PD-1 
blockade is well tolerated and results in overall response rates of over 80% in the relapsed and 
refractory setting(34), severe life threatening complications were not seen until patients underwent 
allogeneic haematopoietic cell transplantation.(46)  This type of data relied on astute clinicians 
identifying the occurrence of toxicity in an unusual context or presentation.  Other such examples 
include the identification of the association of progressive multifocal leukoencephalopathy(10) 
after rituximab therapy in HIV-negative patients, hepatitis B reactivation with rituximab(47), 
delayed neutropenia with rituximab(48), and an  association of ibrutinib with aspergillosis(49) and 
arrhythmias(50) in haematologic cancers.  There is no formal mechanism for this type of activity, 
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but it is nevertheless of critical importance. Post-marketing surveillance for adverse events is 
further explored in Subsections VI and VII. 
The process of learning from one trial to inform the investigators and clinical practice in 
another trial needs to become increasingly rapid and dynamic, from both regulatory and sound 
clinical practice perspectives.  The rapid roll-out of immunotherapies across tumour types, and 
concurrently into regimens of multiple combinations (including other novel therapies), each with 
a different AE profile, has created regulatory challenges.  Perhaps the most compelling examples 
are the seamless phase 1, 2, 3 designs with large expansion cohorts used in immune-oncology 
trials.  The advantages of this type of design include the ability to rapidly identify areas of disease 
activity and move quickly to licensing strategies.  IRBs were challenged to assure patient safety as 
rapidly disseminating safety information without the added safeguard of a data safety monitoring 
committee proved challenging due to rapid accrual.  These were not insurmountable problems, 
although they did raise ethical concerns.  The risk of not identifying the optimal RP2D always 
exists when compiling non-aggregated data. 
Based on the regulatory experience of the last few years, very rare adverse events which 
were initially unexpected have become common and expected, as with hypophysitis from PD-L1 
inhibition.  Furthermore, given the potential chronicity of therapy - in CML for example - longer 
follow-up may become particularly important as AEs may occur long after the mandatory 
monitoring period has ended.  Furthermore, their pattern may be different at re-starting after a 
deliberate period off-therapy as compared to initial therapy.  For example, late toxicity seen with 
imatinib in chronic myelogenous leukaemia, e.g. cardiac toxicity, abnormal bone and mineral 
metabolism, hypothyroidism, etc, would not necessarily be observed in studies with exclusively 
short-term endpoints.(51)  A greater expectation of the unexpected, which may occur either acutely 
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or quite delayed, requires mandatory, longer term surveillance if safety data are to be captured 
comprehensively, particularly as some treated haematologic malignancies now become chronic 
conditions.  
The need to rapidly capture and transfer AE data also illustrates the need for long-term 
clinical benefit endpoints in later-phase trials.  The desire for quick-answer short-conduct trials 
may short-circuit the ability to define important longer-term toxicity.  The mandatory solution for 
evaluation of longer-term toxicity is long term follow up of patients participating on late phase 
clinical trials. Late occurring toxic effects can adversely affect survival, and this impact can only 
be detected with adequate follow up.  For example, in early stage classical Hodgkin lymphoma, 
when radiotherapy is used compared to standard ABVD alone, PFS is improved with the addition 
of radiotherapy, but OS may ultimately be compromised, likely due to late effects of RT.(52)  Late 
phase trials should be designed to assess the true clinical impact as reflected by PRO measures of 
symptoms or function, in addition to survival.  Shorter term endpoints may have regulatory 
importance in safety assessment, but assessment of longer-term benefit should not be de-
emphasized and has a role in tolerability evaluation 
Data informing late term toxicity may also come from other sources such as post hoc 
analyses with social media and patient advocacy playing an important role.  Examples of this 
include thromboembolic disease with the use of lenalidomide(53) and concerns regarding toxicity 
of steroids in multiple myeloma.  Patient advocates in the Eastern Cooperative Oncology Group 
in the US identified high-dose steroids as a concern, leading to a randomized phase III trial proving 
low-dose steroids with lenalidomide improved survival in multiple myeloma and a subsequent 
regulatory approval in the US.(54)  
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For the AE profile knowledge base of new medicines to evolve, real-time multi-directional 
information transfer between regulators, clinicians and clinical investigators is required.  For it to 
be impactful and to better protect patients in ongoing trials and the clinical setting, the information 
must be made available and must be accurate.  The printed product label may no longer be the best 
method of transfer of AE knowledge for the 21st century, as will be addressed in Subsection VI.  
How AE data are presented can, and should, be much improved, striving for real-time monitoring 
followed by accurate interpretive reporting. 
Complexities of AE assessment unique to haematologic cancers 
The definition of AEs and challenges inherent in AE analysis given the time profile of 
toxicities of existing and novel agents are common between haematologic cancers and solid 
tumours.  However, distinct differences specific to haematological cancers which pose challenges 
to some AE assessment exist and warrant noting.  For example, consider bone marrow involvement 
by tumour, a far more common situation in haematologic malignancies than solid tumors.  The 
gray area between bone marrow toxicity and the desired therapeutic effect complicates AE 
reporting and interpretation of the aggregate data.  The complex supportive management of 
patients with marrow infiltrative disease must be balanced with treatment to avoid infections, 
bleeding complications and other unavoidable AEs brought on by disease or treatment.  Navigating 
around and through these expected events may in some cases be the only avenue for potential cure 
of the underlying cancer.  The grade 3 and 4 haematologic AEs that commonly occur with acute 
leukaemias and aggressive lymphomas are not indicative of a therapy that is not effective or safe.   
Another example where interpretation of clinical and laboratory findings is particularly 
challenging in haematologic malignancies and has the potential to mislead drug development was 
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observed during the development of ibrutinib for the treatment of CLL.  Immediate post treatment 
leukocytosis could be interpreted as either a toxicity of the agent or as disease progression, when 
in fact, it represented the therapeutic effect of ibrutinib.(55)  Therefore, defining DLT-qualifying 
toxicities is challenging in these cases.  Treatment of haematological diseases with haematopoietic 
cell transplantation also requires specific attention to AE reporting that differs from most solid 
tumour settings and this will be addressed in Subsection IV.  Collection of the events is necessary, 
but the appropriate reporting of the AE events must be made in the context of the disease under 
treatment.   
BOX: New contexts of AE evaluation in haematologic malignancies: immune-related AEs 
 Advances in immunotherapy, both with checkpoint blockade, bi-specific antibodies 
and CAR-T cells, has been met with significant practice changing approaches in some 
haematologic malignancies, but also introduces great complexity to AE assessment.  The recent 
FDA approval of CAR-T cell therapy in the United States, and the proliferation of these therapies 
in clinical trials for patients with relapsed haematologic malignancies across many developed 
countries brings along a myriad of immune-related AEs (irAEs) which are not well captured by 
current systems of adverse event assessment.  These immunotherapy-related adverse events have 
brought new challenges to reporting, dose modifications, and subsequent patient management.   
With regards to checkpoint blockade inhibition, the array of immune-related AEs (irAEs) 
continues to grow, and with the chronicity of this therapy in many cases, these AEs arise at 
unpredictable times and their duration in some cases can often be prolonged.  Because of the 
efficacy of these drugs, reporting of AEs has been suboptimal, both because of investigator and 
patient bias towards not wanting to stop an effective therapy.  Unique toxicities with check-point 
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inhibitors include puritis, maculopapular rash, thyroiditis, pneumonitis, diarrhea, colitis, hepatitis, 
arthritis, myositis, nephritis, pericarditis, haematologic toxicities, and neurologic toxicities.  At 
what grade level these and other agents must be discontinued and in what circumstances to retreat 
are not necessarily clear.  The majority of clinically significant irAEs occur early in therapy and 
are reversible with either the discontinuation of the drug and/or the administration of steroids or 
other immune suppression and these for the most part are reported.  However, some occur late in 
therapy, some have been recurrent with or without drug rechallenge, some are low grade but 
chronic, and some have been fatal.  It is these late occurring, recurrent, or chronic low grade irAEs 
that are underreported and clinically underappreciated.  In addition, the definition and recognition 
of an irAE is often the result of a best clinical judgement which involves subjective consideration 
of a differential diagnosis, and it is rarely biopsy proven (ie in the case of ground glass opacities 
that could be due to infection or pneumonitis).  As the spectrum of these irAEs has become more 
defined and we have garnered more experience with their management, the recognition and 
grading of irAEs has become more standardized and management has become more prescribed 
with many sponsors using predefined case definitions.  This alone will certainly improve irAE 
evaluation and reporting with these new agents.  Formally standardizing irAEs and case definitions 
in terms of type and grading across all studies will help further in this regard.(56)  In addition, 
incorporating patient reporting of AEs in addition to physician reporting in to clinical trials and 
post-commercialization will deepen our appreciation for how these irAEs affect a patient on a 
potentially chronic or long term therapy, as will be discussed in Subsection II. 
CAR T cell therapy, on the other hand, poses a potentially opposite problem.  In this case 
the therapy is acute, not chronic, and has a defined and relatively limited array of toxicity largely 
falling into two distinct categories – cytokine release syndrome (CRS) (57) and neurotoxicity.  
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Regarding CRS, the pathophysiology is fairly well understood and effective therapies exist so 
thankfully this is largely a time-limited and reversible risk.  Regarding neurotoxicity, the 
pathophysiology is not clearly defined and how to best manage these patients is also unclear.  As 
with CRS, the vast majority of cases are time-limited and reversible but rare cases of protracted 
neurotoxicity and/or death have been reported.  The standardization of a CRS and neurotoxicity 
classification and grading system by Lee et al(57) that is used across most studies has helped to 
better characterize these AEs, although the grading, especially for neurotoxicity, remains 
somewhat subjective with room for improvement, and not all studies use the same grading system 
(UPenn and Novartis have a separate grading system, whereas most other use the Lee criteria).  
The FDA is testing the feasibility of keeping a safety database that cross-references safety 
information across multiple different INDs for CAR T cell products that is aimed to promote 
dissemination of new safety information both within the FDA and to study sponsors.  Such shared 
community data would be important and similarly helpful for checkpoint inhibitors in addition to 
CAR T cell therapy.  However, unlike with checkpoint inhibitor therapy, the AE reporting 
following CAR T cell therapy is fairly accurate but is potentially overemphasized given the high 
intensity but time limited risk of this therapy on the one hand, and the high clinical impact and 
efficacy on the other.(58)   
With both therapies, however, post-market approval AE reporting becomes incredibly 
important and is likely to fall short.  As these drugs and therapies are given to patients who are not 
the perfect clinical trial candidates, with comorbidities that were either not included on previous 
trials or that were explicitly excluded, and following therapies that had not been previously 
explored, the risk of these AEs may change dramatically, as will be addressed in Subsection VII.  
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Better tools and strategies for post-marketing AE evaluation and reporting are required to best 
understand from a risk-benefit ratio who should be receiving these therapies off trial.  
Ultimately, vast changes in treatment paradigms for haematologic malignancies should 
spur changes in our current systems of AE assessment, analysis and rethinking of early and late 
phase clinical trial designs (Table 5).  The ascertainment and reporting of AEs would also be 
enhanced by inclusion of patient-reported outcomes as discussed in the next subsection. 
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Subsection II: Incorporation of Patient-Reported Outcomes in AE Evaluation 
 
Advances in the understanding of tumour biology, immunology and genetics have led to 
drug and biologic products that can produce deep and durable anti-tumor effects and improved 
survival in patients with haematologic malignancies.(59) The welcome advances in outcomes with 
newer therapies are not without costs. Safety profiles of anti-cancer drugs are moving from a 
characteristic group of acute toxicities that recover between intermittent dosing, to potentially 
prolonged symptomatic side effects that are heterogeneous in type and kinetics.  These 
symptomatic AEs may lead to dose modifications, elective patient discontinuation or poor 
adherence to long-term treatment plans, and can significantly compromise a patient’s quality of 
life.  The changing safety profile of cancer drugs has led to a call to rethink old practices and 
consider new methods to assess, analyse and interpret cancer product safety and tolerability as 
discussed in the preceding subsection.(60)  In addition to standard routine clinical visits and 
clinician reporting of AEs, incorporating the patient in the assessment of cancer therapies is of 
great interest both in the clinical trial and clinical care settings.(61)  
Some haematologic malignancies are now chronic conditions, which creates a challenge 
and opportunity to assess the toxicities of prolonged, continuous therapies as part of usual daily 
life, as opposed to short-course cytotoxic therapy intended to cure. The acceptable toxicities 
between these two different scenarios are likely different, and our understanding can be enhanced 
with the use of longitudinal patient reported outcome (PRO) data.  This subsection will focus on 
the role of PROs in enhancing our understanding of toxicity in haematologic malignancies. 
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Patient Reported Outcomes, Health-related Quality of Life and PRO-CTCAE 
Patient-reported outcomes (PRO) are assessments based on a report that comes directly 
from a patient about the status of a patient’s health condition without amendment or interpretation 
of the patient’s response by a clinician or anyone else.(62) The term PRO is often confused with 
the term “health-related quality of life.” PRO is a broad term describing an assessment method 
whereas health-related quality of life is a specific clinical outcome. In some cases, a clinical 
outcome may be assessed by various methods. For example, the clinical outcome of physical 
function can be measured by a PRO, a clinician-reported outcome assessment (e.g. Karnofsky 
Performance Scale), or a performance outcome assessment (e.g., 6-minute walk). Increasingly, 
there is also interest in the use of wearable devices to quantify a patient’s activity in daily life as a 
clinical outcome. 
Health-related Quality of Life (HRQL) is a clinical outcome that is assessed using a PRO 
measure.  The outcome of HRQL is a multidimensional construct defined as the subjective 
perception of the impact of health (including disease and treatment) on physical, psychological 
and social functioning and well-being.(63) Typically, HRQL assessments in clinical trials are used 
to evaluate the effects of cancer and its treatment in aggregate on the patient’s perception of well-
being, as a supportive outcome to complement the usual primary outcomes of disease control and 
overall survival. 
The use of PROs in clinical trials can help to refine the understanding of patient benefit or 
harm when there are clear objectives for their inclusion. PRO assessments have provided important 
complementary information from the patient’s perspective on functional outcomes and the 
trajectory of symptoms over time.(64)  However, PRO assessments of generic HRQL measures or 
disease modules may not always incorporate the symptoms of interest for the diversity of novel 
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therapies being investigated. Developers of commonly used PRO measures of HRQL, such as 
European Organisation for Research and Treatment of Cancer (EORTC)(65), Functional 
Assessment of Chronic Illness Therapy (FACIT)(66), and the EuroQOL 5D (EQ-5D)(67) have 
developed standard disease modules which are specific sets of questions assessing symptoms 
typically seen with the specified disease and side effect profiles of some common standard 
therapies. The questions included in these modules do not vary and do not have the flexibility to 
adjust to differing toxicity profiles seen with the wide range of drug classes currently in 
development for haematologic malignancies. For instance, rash and ocular side effects may not be 
assessed in older generic tools.  In addition, existing HRQL tools are often designed without 
assessing the burden and incentive of patients to provide meaningful data, further decreasing the 
validity of current HRQL approaches. Involving patient organisations in the development and 
validation of such tools may drive acceptability and data validity. 
Increasingly, efforts have been made to overcome this lack of flexibility by incorporating 
additional ad-hoc questions on symptoms or side-effects to capture additional AEs of the new 
treatments. Both EORTC and FACIT organizations have publicly accessible item libraries of 
questions which allow physical symptoms to be selected to fit the context of the trial. This is a 
reasonable approach, but the symptom items in the generic forms may still include those which 
are not typically expected to occur (e.g. peripheral neuropathy in a trial with drugs that do not have 
that specific toxicity previously recognised). 
While HRQL and its functional domains (e.g. physical, cognitive, emotional) can be 
affected by the toxicity of a therapy, increasingly there is interest in specifically assessing 
symptomatic treatment-related side effects using PRO measures to complement clinical 
understanding of safety and tolerability. The U.S. NCI recently developed the Patient-Reported 
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Outcomes version of the Common Terminology Criteria for Adverse Event (PRO-CTCAE™) 
specifically for self-reporting of symptomatic AEs, mapping to the well-established CTCAE 
system for clinician reports. This item library for patients contains 124 PRO questions reflecting 
78 symptomatic AEs, which is derived from and designed to be used alongside standard clinical 
reported CTCAE assessments.(68) PRO-CTCAE is flexible such that applicable AEs can be 
selected for administration depending on the expected side effects of the given clinical trial. PRO-
CTCAE has demonstrated positive psychometric properties including construct validity, reliability 
and responsiveness.(68, 69) With PRO-CTCAE, patients score separately the different aspects of 
a symptomatic AE, such as the presence, frequency, severity and/or activity interference associated 
with each term. Thus, PRO-CTCAE scores do not correspond to clinician CTCAE grades. This 
difference permits the analysis of patient-reported interference separate from severity, which may 
lead to insights for tolerability. 
Patient Reported Outcomes in Existing Haematologic Malignancies Trials 
Many clinical trials in patients with haematologic malignancies have not typically 
incorporated HRQL or other PRO assessments. Data from NCI-sponsored clinical trials from 2004 
through 2016 show that less than 10% of the clinical trials with leukaemia, lymphoma and 
myeloma patients have included PRO or HRQL endpoints (Table 6). The myeloma phase 3 trials 
were more likely to have HRQL endpoints than any other trials.  
Multiple myeloma is a chronic malignancy characterized by significant symptoms related 
to disease burden (e.g., bony pain, fatigue) and treatment toxicity (e.g., neuropathy). In recent 
years, many new agents have been approved that have increased the survival in this incurable 
disease, with a shift from intensive induction therapy to a chronic delivery of therapy. Increasingly, 
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PROs are being incorporated into clinical myeloma trials to assess the impact of treatment on 
HRQL.(70) Two systematic reviews showed the inclusion of HRQL assessments in myeloma 
clinical trials to be limited but increasing, and the analysis of HRQL assessments showed 
significant symptomatic improvement during first-line therapy.(71, 72) Inconsistencies in the 
incorporation and analysis of HRQL in these trials, however, makes interpretation of these findings 
and cross-trial comparisons challenging.(71) 
In addition to measurement of a drug’s effect, PRO data can inform how patients are 
affected by their disease course. For example, the Eastern Cooperative Oncology Group (ECOG) 
incorporated longitudinal measurement PROs in the E4402 study comparing rituximab 
maintenance and re-treatment strategy in patients with low-grade NHL.(73) The trial reported 
similar illness-related anxiety, overall anxiety, and HRQL between the groups. Investigators 
concluded that relapse may not be not associated with increased anxiety as previously thought, and 
the retreatment strategy resulted in similar patient outcomes while utilizing fewer resources.(73) 
The international phase 3 trial of watch and wait versus rituximab induction versus rituximab 
maintenance included HRQL at 7 months as a primary endpoint. The patients on the rituximab 
arms had improved progression-free survival and time to chemotherapy or radiation therapy. The 
patients on maintenance therapy had improved mental adjustment to cancer scores compared to 
those on watchful waiting, although no difference in overall QOL, anxiety, depression, or distress 
as measured by Impact of Events-Scale.(74)   
HRQL and other more defined PRO measures of patients function in these trials can 
provide additional information to understand the overall effect of the disease and treatment and 
brings the patient’s perspective into the treatment evaluation. However, the multi-dimensional 
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construct for HRQL may not provide the specificity to understand what symptomatic toxicities 
may be driving the tolerability of a specific regimen. 
Safety and Tolerability 
Safety and tolerability are critical, but capture different aspects of a regimen’s effect on 
patients. Safety is intended to reflect the medical assessment of an AE that occurred to a patient 
based on the clinician’s judgement about information such as medical history, physical 
examination, laboratory and imaging findings. Tolerability reflects the extent to which overt AEs 
impact the patient’s willingness and ability to continue the treatment regimen (see Figure 5 and 
Figure 6).(75, 76) 
As discussed in the prior subsection, the primary method for assessing and reporting safety 
is clinician-graded AEs based on the CTCAE that are reported in tables of the worst grade 
events.(62)  These tables quickly and effectively communicate safety according to the numbers of 
patients who experienced the worst severity of toxicity at any point in time. However, they do not 
provide specific information on when the AEs developed, resolved, or improved with supportive 
interventions which are clinically relevant issues with the long-term, chronic, orally administrated 
agents (or regimens).  These aspects may be highly relevant to tolerability, even if they do not 
specifically impact safety.  Novel graphical or analytic approaches such as those presented in the 
prior subsection are necessary to incorporate the time profile of AEs of several novel agents. 
“Low grade” AEs are not often the focus of safety assessments and may not be recorded 
on case report forms in many cancer trials. Whereas a low-grade change in potassium may not be 
important to patients, low grade symptomatic AEs, such as nausea, diarrhea or neuropathy, can be 
burdensome to patients, particularly when persistent, chronic or cumulative. Low-grade 
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symptomatic AEs have resulted in patient non-adherence to therapy.(77-80) Targeted therapies 
often are associated with a spectrum of non-specific AEs that may not be frequent or severe, but 
alter patient HRQL.(81) Studies have demonstrated that clinicians may underestimate the 
incidence and severity of symptoms, compared to patients’ self-reports of similar information 
generated from PRO measures.(82-84) This difference in clinician and patient responses provides 
some of the distinction to illustrate the differences between safety and tolerability.(85) A patient 
may have severe nausea that decreases food intake, but he or she is able to drink fluids and is not 
dehydrated. This patient would likely rate his or her nausea as severe; however, the clinician would 
categorize this nausea as grade 2 by CTCAE. While a short course of treatment with the regimen 
causing this nausea may be tolerable over a few cycles, it is unlikely to be tolerable over months 
to years of treatment.  
Increasingly, the nature of treatment for haematologic malignancies is resulting in chronic 
administration of oral medications. Understanding tolerability of agents over time, such as by 
incorporating methods such as AUC evaluation for toxicity as previously discussed, is essential to 
maximize patient benefit. Definitions of toxicity relative to drug exposure are helpful to clarify the 
time-related function of AEs relative to drug exposure (Subsection I, Table 1). The inclusion of 
patient-reported symptomatic AEs through tools like PRO-CTCAE, can provide additional data 
that is complementary to safety data. PRO strategies should begin with a baseline assessment with 
longitudinal assessments throughout and at the end of treatment, as well as multiple analytic and 
visualization techniques.  
Incorporation of HRQL and other PRO measures to inform the patient experience while 
exposed to a cancer therapy can add value to our understanding of the effect of a new intervention. 
Efforts are underway at standardizing how PRO measures can be analysed and presented.(86, 87) 
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There is now growing interest in utilizing item libraries, such as the PRO-CTCAE, to provide the 
needed flexibility to select the relevant emergent symptomatic AEs for the trial context that can  
inform drug safety and tolerability in addition to measuring HRQL. 
Statistical Analysis Opportunities for PRO Data 
Standardizing PRO assessment and analysis in cancer trials is critical, and several 
international collaborative efforts are underway in key areas including identifying core outcome 
sets (COMET, ICHOM) (88, 89), standard PRO analytic methods (SISAQOL)(86), and standard 
PRO protocol elements (SPIRIT-PRO)(21).  
Statistical analysis approaches for PRO data are well established(90) and may include 
cross-sectional mean estimation with comparisons at key time points using t-tests or analyses of 
covariance where the baseline PRO score is included as a covariate; longitudinal mean estimation 
with comparisons using generalized linear mixed modeling (GLMM) or generalized estimating 
equations; or summary measure approaches exemplified in the prior section (e.g., area-under-the-
curve, responder definitions) with between-arm comparison using an applicable statistical 
comparison approach. 
PRO data analysis should carefully handle missing data and multiplicity. The very best 
approach to handle missing data is to minimize its occurrence through thoughtful design and 
enhanced data collection and monitoring.(91) Reasons for missed reports should be captured 
during data collection and reported in manuscripts(92) to understand how the missing data might 
bias results. The best statistical approach in the presence of missing data is a method which uses 
all available data and is robust to some types of missing data, followed by sensitivity analyses 
which employ a range of missing data methods (e.g., GLMM), to assess the robustness of results 
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to various missing data assumptions. Multiplicity is commonly handled using a hierarchy approach 
where each PRO endpoint is identified as a primary, secondary, or exploratory endpoint. Other 
methods include alpha adjustment methods (e.g., the Bonferroni method), resampling methods, or 
global tests (e.g., O’Brien’s test). As is the case with CTCAE safety data, multiplicity is not a 
concern when PRO-based AE data are presented in a descriptive fashion without formal statistical 
comparisons. 
Clinician-based AE data are commonly reported using summary measures where the 
maximum grade during treatment of each AE is computed per patient and then summarized across 
patients using frequencies and percentages. Subsets of AEs may also be summarized (e.g., only 
AEs which are at last possibly related to treatment). Alternative approaches include longitudinal 
modeling or competing risk methodology. 
Opportunities exist for developing optimal strategies for the estimation and visualization 
of PRO-based AE data. PRO-based methods which typically rely on estimating severities (in trial 
participants in aggregate) may not adequately communicate findings to a clinical audience who is 
accustomed to standard AE reporting of percentages of patients with each CTCAE grade level. 
Summary approaches typically applied to CTCAE data may not adequately address missing PRO 
data issues nor properly account for baseline symptoms. An alternative summary measure 
approach taking the baseline score into account(93) has been proposed which mirrors how 
clinicians are trained to identify AEs. If a symptom is present at baseline, then it may be considered 
an adverse effect if it worsens during treatment. Thus, in the proposed baseline adjustment 
approach, PRO-based AE scores which are the same as or improved from baseline are converted 
to a score of zero, and scores which are worse than baseline are analysed without modification. 
Taking baseline into account holds the potential to improve attribution of an AE to the drug under 
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study; a particularly challenging issue in cancer trials with residual toxicities and cancer related 
symptoms at baseline. Alternative methods which have yet to be fully explored for PRO-based AE 
data may include joint modelling of PRO-based AE data with CTCAE data and/or disease status, 
or multiple imputation approaches which use clinician-based CTCAE data as auxiliary data. 
Electronic Collection of Patient-Reported Outcomes 
In addition to novel methods for analysis of PRO data discussed above, opportunities exist 
for improving collection of PROs in patients with haematological malignancies, both in the clinical 
trial setting and the practice setting. The traditional paper collection of PROs may be burdensome 
to patients and staff, particularly in the setting of inadequate resources and infrastructure. The 
telephone or electronic collection or PROs may ease some of these burdens in that it eliminates 
the need for printing, dissemination and collection of questionnaires, manual scoring, and entry 
into a database. Electronic collection of PROs is reliable, valid, and may be preferred by 
patients.(94) 
Despite the rapid uptake of electronic devices from smartphones to tablets for 
entertainment, shopping and banking, the incorporation of electronic PROs has been relatively 
slow in non-industry sponsored cancer clinical trials. There is a perception by clinical staff and 
trial investigators that patients are unable or unwilling to use electronic devices, particularly 
elderly or frail patients. Yet, a recent Pew Report shows that roughly two-thirds of those over 65 
years of age are going online, and more than 40% have smartphones with the rate of adoption 
rapidly increasing.  This is occurring even as many seniors acknowledge the need for additional 
help.(95) 
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Cancer patients themselves are interested in PROs. The global patient organisation CML 
Advocates Network initiated an online survey across 63 countries to better understand the extent 
and drivers of non-adherence. Over 2500 CML patients completed the web- and paper-based 
survey which showed that adherence correlated with key factors which could be influenced 
through improved doctor-patient communication such as management of side effects and 
satisfaction with level of information about disease. The survey noted that only 32.7% of CML 
patients were highly adherent to CML therapy, despite a clear correlation of adherence with 
therapy outcomes. (80)  
With the widespread use of Electronic Medical Records, it is now feasible to incorporate 
and display the patient self-reported disease symptoms and AEs in the medical records. Yet many 
clinicians are reluctant to embrace electronic methods for collection of patient-reported toxicity, 
concerned about the security of data, patient privacy and confidentiality, the potential to be 
overwhelmed with a large electronic workload and clinical practice burden caused by potential 
need for clinical (MD or RN) response to a patient-reported symptom or toxicity. These concerns 
are not insurmountable, particularly as evidence emerges supporting the potential benefits in 
communication and management of symptoms in the clinical care setting. 
Clinical trials evaluating integrating patient-reported symptoms into the routine care of 
cancer patients have suggested that this approach can improve physician-patient communication, 
result in better symptom control for individual patients, reduce patient distress, and have a positive 
impact on patients’ QOL.(96, 97) A recent study demonstrated that electronic PRO collection of 
symptoms in patients with advanced malignancy improved HRQL, decreased emergency room 
visits, and resulted in increased survival with greater benefits reported by those patients with less 
computer experience.(98) 
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Ultimately, electronic collection enables the patient to report symptomatic AEs in “real-
time” as they develop, allowing early intervention with supportive medications. Further studies of 
the ease of workflow in clinics, acceptability by patients and providers, generalizability, and 
compliance will be necessary to understand the impact and implement in both clinical trials and 
clinical care.(99-101) 
 Evolving treatment paradigms in many haematologic malignancies and the proliferation of 
chronically administered agents across many different diseases have generated new challenges in 
understanding side effects and how they affect our patients. Assessment of tolerability is as integral 
as safety of the drug as therapy moves beyond a limited window for cytotoxics and to months or 
years with novel targeted agents and immune therapies.  Incorporation of PROs into AE 
assessment holds great promise to inform our understanding of tolerability going forward. 
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Subsection III: Special Issues of Toxicity in Haematopoietic Stem Cell Transplant 
Capturing and Evaluating Toxicities Post-Hematopoietic Cell Transplantation 
The prior subsections have addressed the importance of how AEs are defined, collected 
and analysed, and the rising need for PROs to enhance tolerability assessment.  The focus of this 
subsection is specifically on AEs of hematopoietic cell transplantation (HCT), a potentially 
curative procedure used to treat life-threatening malignant and non-malignant haematologic 
disorders. It is a complex therapeutic approach that often involves administration of high doses of 
cytotoxic and/or immune suppressive agents. These agents can induce a myriad of toxicities and 
HCT therefore represents a unique situation in toxicity assessment in haematologic malignancies.  
This subsection will review special issues pertaining to AE assessment in HCT including multiple 
complex toxicities, graft versus host disease in allogeneic transplantation, AEs related to HCT 
specific polymedication, infectious AEs, and select longer term AEs post-HCT including sexual 
dysfunction, infertility, secondary cancers, and neurocognitive impairment.   
AEs of HCT include prolonged cytopenias and impaired innate and adaptive immune 
responses leading to opportunistic infections, organ toxicity, particularly (though not limited) to 
the lungs, liver kidney and gastrointestinal tract, and therapy-related cancers.  Toxicities are related 
to the conditioning regimen and may be influenced by the inclusion of total body irradiation. 
Regimen-related Toxicities have been graded by the Bearman Scale(102) or the National Cancer 
Institute  Common terminology Criteria for Adverse Events (CTCAE) version 4.0.(37)  
Allogeneic HCT involves infusion of genetically disparate grafts with the potential for 
graft-versus-host disease (GVHD) which can be itself life-threatening and require prolonged 
immune suppressive therapy contributing to the emergence of opportunistic infections. Acute 
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GVHD arises when donor graft immune cells recognize host tissue as foreign, and injures skin, 
gut and liver. The Seattle (103) and IBMTR(104) grading systems are in use to document the 
severity of acute GVHD and, despite some limitations, are commonly employed. In contrast, 
consensus on the diagnosis, staging and response criteria for chronic GVHD has been challenging. 
Based on data from the Chronic GVHD Consortium, the 2014 NIH Consensus Conference has 
proposed a scoring system for chronic GVHD from an assessment of eight organs from which the 
NIH Global Severity Score is derived.(105) 
There are few, if any, HCT recipients who do not experience at least one serious AE and 
the overwhelming majority will experience more than one. Reporting the myriad of expected AEs 
in the early HCT setting is often cited as a barrier to performing clinical trials of agents in HCT. 
The barrier comes not only from the frequency of the events but also the long list of concomitant 
medications that must be reported in traditional AE reporting systems, since polypharmacy is the 
rule for patients in the first few months (and sometimes longer) after HCT. Additionally, 
attribution is often difficult and sometimes impossible in the setting of multiple competing risks. 
The frequency of AEs and their “expectedness” also makes under-reporting an issue, when 
guidance is not specific (other than the usual definition of serious AEs) and when surveillance is 
not standardized. This is not only true for HCT but has been demonstrated in pediatric acute 
leukaemia where use of automatic reviews of laboratory values through the electronic health record 
demonstrated under-reporting of several organ toxicities(106). However, it may be even more 
important for HCT, where the significance of a particular AE in a specific setting or trial can only 
be ascertained by understanding its frequency in relation to what is expected.  
Taking a “realistic” approach, the Blood and Marrow Transplant Clinical Trials Network 
(BMT CTN), a US National Institutes of Health supported trials group, has developed a model 
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where only unexpected grades 3-5 AEs are reported in an expedited case by case manner while all 
expected events are reported on calendar-driven case report forms. The amount of data regarding 
concomitant drugs is limited to what is considered essential. Independent Medical Monitors 
(typically transplant physicians or disease matter experts) provide unbiased reviews of unexpected 
(or more frequent than usually expected) events. Additionally, estimations of expected rates of key 
toxicities that might be of particular concern, because of the drugs or strategies being tested, are 
defined in the protocol and monitored specifically with a sequential probability ratio test (SPRT) 
which allows the medical monitor and Data and Safety Monitoring Board to know when the 
observed rate is above the expected.  Briefly, at each monthly interim analysis, the total time on 
study is plotted against the total number of patients experiencing the toxicity of interest, (e.g., 
veno-occlusive disease or graft failure) patients experiencing death)(107).  If the number falls 
outside the previously defined acceptable boundary, the SPRT rejects the null hypothesis, and 
concludes that there are more events than predicted by the observed time on study.   
This lean AE reporting process allows the Network to minimize the data reporting burden 
for centers, to ensure that all important toxicities are captured and to separate issues of real concern 
from the background. The approach was effective in the early detection of events that led to closing 
the umbilical cord blood cohort of an unrelated donor transplant trial for sickle cell disease and 
exclusion of busulfan-conditioning regimens from a trial evaluating sirolimus for GVHD 
prophylaxis after treatment of only eight and ten subjects, respectively.(107, 108) This is a far 
more effective model than the one-by-one AE reports of common HCT-related toxicities.   
Fortunately, the field of HCT is characterized by the existence of large national and 
international outcomes registries such as the Center for International Blood and Marrow 
Transplant Research (CIBMTR) and the European society for Blood and Marrow Transplantation 
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(EBMT) that systematically collect data on many toxicities that can aid in estimating expected 
rates and understanding HCT toxicity better.  In the United States, reporting outcomes of 
allogeneic HCT recipients to a national registry managed by the CIBMTR has been mandatory 
since 2006. The CIBMTR systematically collects data on all recipients through two years 
following transplantation and attempts to maintain follow-up on patients through their transplant 
centers for as long as possible, with data on more than 15,000 15-year survivors.  The CIBMTR 
captures key clinical data entered by centers through an electronic data collection system, but is 
limited in its scope due to funding constraints.(109)  Limitations to the large-scale registry include 
patient loss-to-follow-up, burden of data submission and limited data on the patient perspective on 
quality of life and AEs. Nevertheless, a particular strength of CIBMTR outcomes data is the 
reliability of identifying causes of death in the post-HCT period, as demonstrated in Figure 
7.  These data serve as a guide to the likely SAEs encountered after HCT and avoid centre- and 
regimen-specific biases reported in the literature from single institutions. 
In a similar manner, the EBMT which is a voluntary organization comprising more than 
500 transplant centers from around 60 different countries (outside north America) established a 
comprehensive transplant registry collecting outcomes data. Accreditation as a member centre 
requires submission of minimal essential data from all consecutive patients to the central registry 
in which patients may be identified by the diagnosis of underlying disease, type of transplantation, 
and transplant-related events. The EBMT registry  enables  detailed analyses of  transplant 
complications and consequences to be undertaken, giving a real-life picture from  many parts of 
the world. The EBMT and CIBMTR registries represent an unparalleled opportunity to refine the 
identification process of transplant-related toxicities.  While, the safety and efficacy (“estimate of 
effect under ideal circumstances”) of a newly approved agent is usually established,  post-
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regulatory appraisal relying on specific and comprehensive data collection from the registries, will 
likely demonstrate  clinical effectiveness and longer-term safety more effectively (the “real- 
world” effect). 
The US FDA and most other international competent health authorities have grappled with 
the challenges of identifying drug-related toxicity in the context of numerous comorbidities and 
transplant/regimen related toxicity. The defibrotide approval in the US and Europe for the 
treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD) with renal or 
pulmonary dysfunction after HCT highlights many of these challenges. Approval was based on 
Day +100 survival after transplantation across four clinical studies. A CIBMTR registry study and 
the published literature were used as benchmarks for historical control survival rates to assess the 
clinical benefit of defibrotide. For severe VOD, a randomized study compared with placebo would 
have lacked equipoise and posed an ethical challenge. The FDA review team assessed the benefit-
risk to be favorable because the safety profile appeared reasonable “when assessed in the context 
of the treatment of a life-threatening disease with no approved therapy options; however, the safety 
assessment is limited by the lack of complete controlled safety data.”(110) 
To help address these issues we propose that the haematology community optimize their 
strategies and develop consensus on which post-HCT AEs should be considered “expected”, 
depending on graft source and transplant regimen, and on acceptably streamlined approaches to 
capture and analyse these so that unexpected increases in frequency can be detected without 
causing undue reporting burden to clinicians and research staff. Such a system should be evaluated 
and, we hope, advocated by regulatory authorities who play a key role in determining how trials 
are performed, particularly in the corporate sector. Automated approaches to assessing data 
Final author’s draft of a paper accepted for publication in the Lancet Haematol 12 Jun 18 doi: 
10.1016/S2352-3026(18)30051-6. 
44 
 
routinely captured in the electronic health record could potentially also help ensure complete 
reporting of AEs. 
Drug interactions 
In addition to being subject to unique and multiple toxicities, HCT recipients receive 
complex medication regimens comprising cytotoxic agents, immunosuppressants, antimicrobials, 
supportive and targeted therapies in many different combinations, and consequently the potential 
for a drug-drug interaction as an AE is high. Most drug-drug interactions in HCT result in 
alterations in drug concentration, occur most often within the gut and liver and involve cytochrome 
P-450 (CYP450)-mediated metabolism, inhibition or induction.(111) For example, fluconazole is 
a moderate inhibitor of CYP3A4 and posaconazole is a strong inhibitor; therefore, both impact 
metabolism of the CYP3A4 substrates, tacrolimus and sirolimus(112, 113). However, dose 
adjustments required when the agents are used concomitantly are highly variable, ranging from 
25-90%, due to differences in competitive and non-competitive inhibition (9,10). CYP-mediated 
interactions can also be responsible for toxicity with use of otherwise relatively benign agents, 
such as non-absorbable oral steroids.(114) Genetic polymorphisms further complicate potential 
CYP interactions and the frequencies and types are highly variable among different ethnic 
groups.(111, 112)  The Clinical Pharmacogenetics Implementation Consortium (CPIC) has 
published guidelines on dose adjustments according to CYP polymorphism status for select drugs, 
such as tacrolimus. It is recommended to check CYP polymorphism status in patients receiving 
medications that have pharmacogenomic guidance available, although the impact on metabolism 
is known for very few drugs. Nonetheless, checking for CYP polymorphisms in patients exhibiting 
signs of unusual drug metabolism without other identifiable causes is important.       
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Pharmacodynamic interactions due to the physiological activity or effects of a drug are also 
important as exemplified by increased incidence (10-15%) of thrombotic microangiopathy (TMA) 
when tacrolimus and sirolimus are used in combination, versus when each is given alone  
(<5%)(115). Some of the most frequent pharmacodynamic interactions in HCT are QTc 
prolongation and myelosuppression, common adverse effects of many of the medications used in 
HCT. Agents most highly associated with QTc prolongation include: fluoroquinolones, azole 
antifungals, antiemetics (5-HT3 antagonists, dopamine receptor antagonists, atypical 
antipsychotics), and tyrosine kinase inhibitors. Myelosuppression frequently occurs with 
immunosuppressants (mycophenolate mofetil), antivirals (ganciclovir/valganciclovir, cidofovir), 
and targeted therapies (ruxolitinib, ibrutinib)(112). It is therefore important to consider these types 
of drug interactions when initiating medications and monitor the patient for AEs potentially related 
to pharmacokinetic or pharmacodynamic alterations    
 
Infectious complications  
Infectious complications are common after HCT and prove to be difficult AEs to 
characterize and report.  Different patterns of infection occur at different times and the risk and 
type of infectious syndrome varies according to time after transplant and severity and type of 
immune compromise. (116, 117) Infectious complications frequently occur with or after other non-
infectious complications, particularly those that compromise host anatomical barriers (eg, oral or 
gastrointestinal tract mucosa) and events that impede immune reconstitution. Thus, the risk for 
infectious AEs can only be interpreted in the context of other toxicity AEs. 
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 Severity of infectious AEs is also difficult to categorize.  To date, only one severity grading 
system in HCT recipients has been subjected to validation with survival.(118)  Of the three grades 
described, only grade 3 (the highest degree of severity) was associated with survival (p<0.0001). 
Unfortunately, that scoring system has limitations.  Both severity of infection and resource 
utilization, such as the need for more complicated therapies (intravenous antimicrobial therapy or 
hospitalization), were used to drive grading. Although satisfactory more than a decade ago, during 
the past decade, numerous therapies have become oral or are now routinely managed in an 
outpatient setting. Moreover, the scoring algorithm did not include a number of infectious 
complications that now occur. To address these limitations, the BMT-CTN developed a severity 
algorithm to monitor infectious AEs in its clinical trials(119), but to date it has not been validated 
with survival.  
There are frequent ascertainment biases in measuring infectious risk in HCT trials. Two 
common sources of bias are: unfamiliarity with infectious disease definitions, and lack of complete 
diagnostic assessment.  Lack of familiarity with infection definitions often leads to over-estimates 
of certain infectious complications. In contrast, incomplete diagnostic assessment frequently 
under-estimates other infectious events and unduly relies on empiric antimicrobial therapies. The 
aggressiveness of diagnostic assessment varies among centers making cross-center comparisons 
difficult. Moreover, differences in antimicrobial practices can influence the rates and types of 
infections.  Several studies emphasize the need for audits of data reports by experts knowledgeable 
in the diagnostic criteria.(120)   
The above considerations emphasize current challenges for infectious AE assessments.  
Validation of a modern severity algorithm is a priority.  In studies where infectious AEs are 
primary endpoints or important secondary endpoints, specific training of study personnel at study 
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sites and external auditing of data reports are important for accurate AE assessment. Additionally, 
standardization of diagnostic assessment strategies and antimicrobial use is important to reduce 
inter-center variability.   
Sexual dysfunction and infertility  
  Sexual dysfunction and fertility issues are to be considered among the serious AEs after 
HCT, as well as in survivors of some haematologic malignancies who did not undergo transplant. 
Sexual dysfunction in the form of body image problems, lack of desire and impaired physical 
functioning are frequent early after HCT.(121, 122)  Further, it remains a common problem up to 
10-years after transplant in female survivors whereas men are more often able to return to baseline 
sexual function a few years after transplant.(123) Since sexual dysfunction frequently develops 
with or after other complications, the risk of sexual dysfunction AEs can only be interpreted in the 
perspective of other AEs. Sexual dysfunction as a post-transplant AE is often under-diagnosed and 
underreported, in part due to the lack of a specialized team in sexuality at most transplant centres. 
Only 20-50% of patients have a discussion with their physicians regarding sexual health after 
HCT(124). The use of self-reported validated sexuality questionnaires (patient reported outcomes), 
such as the 37 item Sexual Function Questionnaire (SFQ), can help to identify and grade sexual 
dysfunction after transplant (122). Other prospective studies have used other patient-reported 
outcome forms such as the Derogatis Interview for Sexual Function (DISF-SR) or the Sexual 
Problems Measure for assessing sexuality after HCT.(125, 126)  However, the use of different 
questionnaires across studies makes attempts at comparing results between studies problematic. 
The development and validation of a tool combining patient reported outcomes and gradation of 
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AEs is a priority to help to better identify the timing and risk factors of post-transplant sexual 
dysfunction and enable the development of preventative strategies.  
Myeloablative therapy (such as high-dose TBI or high-dose busulfan based regimen 
conditioning regimens) after HCT is often associated with azoospermia and premature ovarian 
failure(127, 128)   There are challenges inherent to the study of fertility rates after HCT, although 
a few studies investigated the rate of pregnancy in survivors or in survivor partners and reported 
pregnancy rates of less than 10%.(129-131)  Potential biases in these studies include lack of 
systematic paternity testing in female partners of male patients and the likelihood that successful 
rather than unsuccessful pregnancies are reported.  Implementing consultative mechanisms for 
fertility preservation prior to treatment as well as family planning during and after cancer has been 
an important priority raised by patient advocacy organizations. 
Although important progress has been made in the field of fertility medicine as less toxic 
conditioning regimens are increasingly used, prospective data on fertility and pregnancy outcomes 
in HCT survivors and their partners are needed .(132) 
Neurocognitive Impairment  
Impairment of neurocognitive function is increasingly recognized as an important adverse 
effect and can be observed within the first 100 days after HCT but also up to 10 or more years 
later.  It can affect up to 50% of transplant recipients.(133)  Functions subject to impairment 
include memory including verbal recall, multitasking, co-ordination, motor dexterity and speed. 
Although a Global Deficit Score has been utilized, a consensus standardized scoring system 
requires confirmation and itemization and may require consideration of the time after HCT:  acute 
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events (within 100 days), dysfunction during the medium (2-5 years; and long term (>6 years). A 
consensus panel to address these issues is encouraged. 
 
Secondary malignancies after HCT 
Different categories of secondary malignancies can occur after HCT, including post-
transplant lymphoproliferative disorders (PTLD), donor type secondary leukaemia/other 
malignancy and de novo solid tumors. TBI and the chemotherapeutic drugs used prior to HCT as 
part of the conditioning regimen can induce new secondary malignancies after HCT. This is 
attributed to the mutagenic risk of irradiation and chemotherapy, the genetic predisposition of the 
patient to develop cancer, prolonged immunosuppression, and in elderly patients, to age-related 
risk. Secondary malignancies after HCT are another example of the myriad of HCT toxicities that 
challenge conventional toxicity reporting.  In Table 7, we summarize many of the issues pertaining 
to AE assessment in HCT, as well as potential solutions.   
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Subsection IV: Long Term Toxicity: Survivorship in Haematologic Malignancies 
 
Long term toxicities such as neurocognitive impairment and sexual dysfunction affect not 
only patients who have undergone HCT but survivors of other haematologic malignancies as well.  
The current subsection will focus on challenges in AE assessment in survivors of haematologic 
cancers.  It is currently estimated that there are 15.5 million individuals living in the US with a 
history of cancer, and this number is expected to increase to 20.3 million by the year 2026.(134)  
Long-term toxicity, or late adverse effects, in cancer survivors result from subclinical or 
asymptomatic physiologic changes that do not cause immediate, intermittent, or short-term clinical 
events, but which, with extended time (many years or even decades), develop into clinically 
manifest adverse effects.  These late effects can substantially impact morbidity, mortality, and 
quality of life and thus are critical considerations when evaluating survivorship in haematologic 
malignancies.   
Heterogeneity of Late Effects in Survivors of Haematologic Malignancies 
There is marked heterogeneity among survivors of haematologic malignancy and, 
therefore, a highly individualised approach is necessary to understand the risk of late effects for 
each patient. Key determinants of late effects include treatments administered to cure or control 
the disease, patient-related factors and the underlying disease itself. 
Treatments are typically considered the most important contributor to the development of 
late adverse effects. Most patients with haematologic malignancies receive systemic therapies; 
fewer patients receive radiotherapy.  For highly curable diseases, such as Hodgkin lymphoma 
(HL), greater emphasis is now placed on selection of initial treatments to maximally avoid late 
Final author’s draft of a paper accepted for publication in the Lancet Haematol 12 Jun 18 doi: 
10.1016/S2352-3026(18)30051-6. 
51 
 
effects. In contrast, for more aggressive diseases or those with greater risk of relapse, higher 
intensity treatment with a curative goal in the near-term is usually considered more important than 
the long-term potential for adverse effects. A new challenge is the greatly improved long-term 
management of a spectrum of haematologic malignancies such as chronic myeloid leukaemia 
(CML), chronic lymphocytic leukaemia (CLL), indolent lymphoma, and hairy cell leukaemia, that 
are generally considered to be incurable but can now be associated with patient survival for 
decades. These entities now require continued focus on treatment of the inevitable relapses of the 
underlying malignancy combined with considerations of potential late-effects. These challenges 
are further confounded by the relatively recent application of new therapeutic classes of targeted 
drugs, for which data on potential late effects are only beginning to emerge. 
Patient-related factors also influence toxicities in survivors of haematologic malignancies, 
either acting jointly with specific treatment exposures or independently of treatment. The can be 
intrinsic factors (e.g., age at diagnosis, sex, inherited genetic susceptibility) as well as lifestyle and 
medical history factors (e.g., cigarette smoking, obesity, exercise). Age at diagnosis is the most 
established patient-related factor that impacts risk for late adverse effects. Although the vast 
majority of cancer survivors are older, haematologic malignancy survivors include many survivors 
of childhood, adolescent, and young adult malignancies. Long-term toxicities are of particular 
concern for individuals diagnosed at younger ages due to the potential for increased susceptibility 
to adverse effects of treatments as well as the decades of survival over which patients may 
experience effects. Some specific issues of concern for younger survivors include pubertal 
development status at treatment and risk of late infertility, the interaction between anthracyclines 
and age at exposure on subsequent cardiovascular disease,(135) the modulating effect of age and 
breast radiation exposure on the risk of second breast cancer,(136) and the devastating impact of 
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childhood radiation therapy on subsequent muscle and bone maturity. There is also emerging data 
suggesting potential interaction between the intrinsic genetic make-up of the individual and the 
impacts of treatment, both in terms of drug metabolism and risk for long-term toxicities.(137)   
Finally, the disease itself may be an important determinant of long-term toxicities, as some 
haematologic malignancies are intrinsically associated with future disorders.  An example is the 
strong relationship between several lymphoid malignancies and subsequent melanoma and non-
melanoma skin cancer,(138) and the increased propensity of long-term survivors of CLL to 
develop infections. 
Late Effects in Survivors of Haematologic Malignancies 
While there are many potential late effects in survivors of haematological malignancies, 
we will discuss three broad categories: second malignancies, cardiovascular disease, and 
psychosocial impairments. 
The development of second malignancies is a major contributor to morbidity and mortality 
among survivors of haematologic malignancies.(139, 140)  Large-scale population-based cancer 
registry studies have quantified specific patterns of risk, which vary substantially for survivors of 
different types of haematologic malignancies. Smaller studies with more intensive data collection 
have identified certain treatment exposures as important risk factors for selected second 
malignancies. However, substantial additional research is needed to discover key risk factors, 
which can then inform long-term follow-up guidelines to screen for second malignancies.  
HL patients, the most studied group of haematologic malignancy survivors, have three- to 
greater than five-fold increased risk of developing subsequent malignancies in or near the 
radiotherapy field. Indeed, the risk of death from second primary malignancy exceeds that of death 
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due to lymphoma itself (Figure 8). This most notably includes cancers of the breast, thyroid, lung, 
oesophagus, stomach, pancreas, and colon for which a linear dose-response of increasing risk with 
increasing radiation dose is observed(141).  Cytotoxic chemotherapy also contributes to risk of a 
number of these subsequent cancers, including a substantially elevated risk for myelodysplastic 
syndrome/acute myeloid leukaemia (MDS/AML).(139)  Reductions in radiotherapy doses and 
volumes of tissue irradiated as well as the shift to less myelosuppressive chemotherapy regimens 
(e.g., from MOPP to ABVD) to treat HL are expected to result in lower risk for subsequent 
malignancies, but long-term follow-up of more recently treated patients is needed to confirm this 
expectation.  
Survivors of other haematologic malignancies also have increased risk of developing 
subsequent malignancies. Chemotherapy-related MDS/AML risks are elevated for survivors of 
nearly all haematologic malignancies.(142)  With the introduction of targeted therapy and the shift 
toward an era of oral chronic therapy (e.g., lenalidomide), monitoring risks associated with novel 
approaches to systemic therapy will be critical. Risks for lung cancer and melanoma after 
CLL/SLL are higher than for survivors of other types of haematologic malignancies, likely due to 
long-term immune dysfunction.(143)   Studies are increasingly evaluating non-treatment risk 
factors for subsequent neoplasms as well. Substantial advances in genomics in the last decade hold 
potential promise for future studies to comprehensively evaluate shared genetic contributors to 
multiple types of malignancy as well as identify genetic susceptibility to treatment-related 
neoplasms.(144)  Other major cancer risk factors (e.g., cigarette smoking, obesity, and alcohol) 
also likely contribute to the occurrence of subsequent neoplasms, although these patterns of risk 
may be similar to those of the general population. 
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Cardiovascular disease is increasingly recognized as one of the leading causes of morbidity 
and mortality among survivors of certain haematologic malignancies. As with subsequent 
neoplasms, a substantial amount has been learned from studying the long-term health of HL 
survivors, who frequently receive both chest radiotherapy and anthracyclines.(145) Risks vary by 
the specific type of cardiovascular disease, emphasizing the importance of detailed clinical data. 
Specifically, increasing dose of radiation to the chest, exposing the heart to larger radiation doses, 
is associated with increasing risk of coronary heart disease, valvular heart disease, congestive heart 
failure, and pericarditis, with risks first evident five years following treatment and persisting for 
decades. In contrast, anthracycline-containing chemotherapy is associated with congestive heart 
failure, with risks sometimes becoming evident during treatment and also persisting for decades. 
Importantly, the true magnitude of risk is likely underestimated in most previous studies, as a 
substantial number of survivors may have some degree of unrecognized and asymptomatic 
cardiovascular impairment.(146)  Because of the potential for larger than additive joint effects of 
these treatments with other cardiovascular disease risk factors, further research is needed to better 
quantify the complex milieu of risk factors present in most patients.(147)  
Survivors of haematological malignancies have an increased risk of psychosocial issues 
compared to the general population, including depression, somatic distress, anxiety, and post-
traumatic stress disorder.(148, 149)   Employment is frequently affected during cancer treatment, 
and changes in work roles often persist long into survivorship.  There is increasing interest in 
studying financial toxicity in cancer patients, and studies report that the economic burden of cancer 
can persist years after diagnosis.(150)  In addition to the issues experienced by “cured” survivors, 
many patients with haematological malignancies have chronic malignancies (e.g. CML, follicular 
lymphoma, etc.), which may create unique anxiety and uncertainty issues.  Development of late 
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medical complications of therapy as well as psychosocial issues are associated with lower quality 
of life.(151, 152)   
Call To Action for Survivor Care: Infrastructure, Funding and Healthcare Delivery 
Thus, a challenge clearly exists:  there is marked heterogeneity in survivors of 
haematological malignancies and the potential late adverse effects are numerous.  To satisfactorily 
capture AEs in survivors, we identify three areas of unmet needs:  1) infrastructure, 2) funding, 
and 3) healthcare delivery (see Table 8). 
Infrastructure 
Quantifying risks of long-term toxicity in survivors of haematologic malignancies will 
require substantial efforts to develop infrastructure for systematic data collection over an extended 
period of time and across the multiplicity of healthcare settings traversed by the patient. Focused 
institutional studies with intensive data collection provide detailed insights into long-term 
toxicities, whereas large-scale linkage studies provide more population-based information on 
larger groups of patients, albeit with less detail. Several ongoing efforts exemplify the tremendous 
promise as well as challenges in collecting data necessary for long-term follow-up studies using 
different strategies.  
HCT survivors have been a focus of study because of their heightened risk of non-relapse 
mortality, well in excess of the general population, long after receiving their definitive therapy 
(Figure 9).  As discussed in the prior subsection, outcomes for HCT survivors are reported to 
CIBMTR.   Much of what is known about the risk of secondary malignancies after HCT across 
specific disease and age cohorts comes from analyses of these data.  Limitations to the large-scale 
registry include patient loss-to-follow-up, burden of data submission and limited data on the 
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patient perspective on quality of life and AEs. Subsection VII will further explore the potential 
expanded role of such registries. 
Two ongoing patient cohorts exemplify the more intensive data collection that also 
includes direct patient contact. The Childhood Cancer Survivor Study (CCSS) is a retrospective 
cohort of >30,000 5-year survivors of childhood cancer diagnosed during 1970-1999 from 31 
institutions in the US and Canada.(153) Detailed data on disease characteristics and treatments 
occurring within the first five years following childhood cancer diagnosis are abstracted onto 
standardized forms at participating institutions. Vital status is updated through periodic linkage 
with the National Death Index in the US, whereas other detailed information on a wide range of 
medical conditions is collected through self-report from patient questionnaires. The Lymphoma 
Epidemiology of Outcomes (LEO) Cohort Study is a prospective cohort study of >12,000 NHL 
patients diagnosed at seven centers in the US. Similar to CCSS, data are derived both from medical 
records and patient questionnaires. These cohorts exemplify the tremendous benefits of capturing 
detailed long-term toxicity data on patients with haematological malignancies, but the resource-
intensive nature of this approach is not feasible across all patients.  However, we must encourage 
additional cohort studies to provide insight into long-term outcomes of patients with other 
haematologic malignancies and receiving a broad range of therapies.   
EMRs hold great promise for improving reporting of all AEs, including patient reported 
outcomes.(106) Unfortunately, substantial barriers remain due to differences in EMRs among 
institutions and the likelihood that survivors will receive care at different institutions during long-
term follow-up.  Resolving these issues to harnessing disparate EMRs and other “Big Data” 
repositories are areas of particular opportunity to expand the study of late AEs. 
Funding 
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Limited availability of funding for longitudinal investigations of long-term toxicity in 
patients with haematologic malignancies is a key barrier to progress. While the last decade has 
seen some progress in new funding mechanisms from governmental agencies, philanthropic 
organizations, and insurance companies, resources have preferentially supported retrospective or 
cross-sectional studies over establishing cohort studies or testing interventions. This problem is 
accentuated in haematologic malignancy, which in 2011 was found to be the focus of only 3% of 
NCI-funded survivorship research.(154)  This challenge is only exacerbated by more recent 
budgetary constraints, which have led to a research climate in which survivorship research must 
compete with basic science and development of novel therapeutics. 
Healthcare Delivery for Survivors 
Long-term cancer survivors are in need of coordinated care that goes beyond surveillance 
for recurrence.  A risk-stratified approach to care, where healthcare services are based on risk of 
recurrence and risk of late effects, has been advocated.(155)  The most intensive approach, a 
multidisciplinary survivorship clinic, is reserved for those at high risk of serious late effects, such 
as HL  patients treated with intensive regimens before 2000 and those who have undergone HCT 
(Figures 1-2). Those at low risk of late effects can be followed by their primary care provider.  
Many survivors fall into the moderate risk category, where shared care between the haematology-
oncology team, primary care team, and perhaps survivorship team is recommended.  However, 
there are few studies that have compared outcomes, specifically identification of AE’s, amongst 
these different models.  In addition, multispecialty survivorship care clinics are generally limited 
to academic medical institutions, which can be a barrier to many patients.  
Given limitations in the present reach of multidisciplinary survivorship clinics, attention 
has been focused on survivorship care plans (SCPs) as a tool to promote coordinated, high-quality 
Final author’s draft of a paper accepted for publication in the Lancet Haematol 12 Jun 18 doi: 
10.1016/S2352-3026(18)30051-6. 
58 
 
survivorship care.  SCPs offer the promise of promoting patients’ understanding of their illness, 
treatment received, risks of late effects, and ability to seek out appropriate surveillance preventive 
healthcare. However, despite repeated calls for increased use of SCPs from the Institute of 
Medicine, broad implementation of SCPs into routine practice has not been achieved.(156)  
Limitations to more broad adoption include: logistical challenges, as preparing an individualized, 
evidence-based SCP is a time-consuming and currently non-reimbursed activity; and scientific 
shortcomings, as few high-quality randomised trials evaluating patient-level impact of SCPs have 
been performed, and many of those that have been conducted have not shown improved outcomes 
for patients.(157)  Despite these barriers, implementation of SCP has become a component in 
cancer center quality review and accreditation processes. Better integration of SCPs within 
electronic health records may lead to improved tailoring of survivorship care,(158) and education 
of haematology-oncology physicians in communication skills inherent to the survivorship 
transition for lymphoma survivors,(159) are two possible approaches to enhance the impact of 
SCPs on the well-being of survivors of haematologic malignancy.  Ultimately, evidence-based 
guidelines for optimal long-term follow-up care of patients are needed.  
In conclusion, there are a burgeoning number of survivors of haematological malignancies, 
with heterogeneity in age, sex, disease characteristics, and treatment exposures.  AEs in these 
patients may include second malignancies, cardiovascular disease, psychosocial issues, and others. 
Given the heterogeneity of the population of haematologic malignancy survivors, improvements 
in infrastructure, funding, and healthcare delivery are essential in order to improve understanding 
of late toxicities and long-term health of these patients. 
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Subsection V: AEs in Haematologic Malignancies & Regulatory Approval 
Traditional AE reporting: Pre-Approval 
Toxicity assessment and reporting are important in the regulatory approval of new drugs.  
International regulatory processes and challenges will be the focus of this subsection.  Although 
regulatory bodies of different countries differ with regard to nuanced details of the regulatory 
process, there are many similarities between the way the US Food and Drug Administration 
(FDA), European Medicines Agency (EMA), Australian Therapeutic Goods Administration 
(TGA), and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) have traditionally 
dealt with toxicity assessments prior to drug approval (see Table 9). Each has basic requirements 
for reporting AEs that cross a certain qualitative or quantitative threshold. In the US, the Code of 
Federal Regulations (CFR) Section 312.32 dictates that sponsors must immediately report serious, 
unexpected, and suspected adverse reactions (SUSARs) that occur on a trial conducted under an 
investigational new drug application (IND).(160) These regulations were amended in 2010 by the 
final rule, which attempted to improve the utility of safety reports and increase the efficiency of 
the reporting process, ultimately to enhance protection of patients enrolled on clinical trials.(161) 
The regulations require periodic review of aggregated safety data to ensure detection of new safety 
signals or a higher rate of serious suspected adverse reactions.  
In the European Union (EU), the clinical trial sponsor is responsible for recording AEs, 
reporting SUSARs to the national competent authority (directly or through the Eudravigilance 
Clinical Trials Module; EVCTM) and the Ethics Committee, and annual safety reporting to the 
national competent authority and the Ethics Committee. The EVCTM is dedicated to the collection 
of Individual Case Safety Reports (ICSRs) for SUSARs in accordance with Directive 2001/20/EC 
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and Regulation (EU) No. 536/2014. Detailed guidance on the collection, verification, and 
presentation of AE/reaction reports from clinical trials using medicinal products for human use in 
the EU is available.(162) The PMDA in Japan and TGA in Australia also require that at least 
unexpected fatal or life-threatening AEs occurring on registrational trials in those countries be 
reported to each agency. Table 9 outlines the similarities and differences between the safety 
requirements of each agency. 
While international regulation has been successful in fostering the safe development of 
therapeutics, harmonization and adherence to regulation of international clinical trials must be 
improved. Minor differences in requirements across regulatory bodies mean that individual 
agencies receive data at different times, potentially leading to variation in the risk-benefit 
assessment at any given time. Moreover, only 14% of the reports submitted in 2015 to the FDA 
Office of Haematology Oncology Products (OHOP) were considered informative (163). This 
potentially translates into a situation where the “noise” of unnecessary safety reports masks the 
true safety signals this reporting is intended to detect. Submission of these reports introduces 
inefficiencies that stand in the way of useful toxicity data that can inform further clinical 
development and regulatory decision making. The time and financial resources required of already 
burdened investigators, nurses, and clinical research professionals serve as additional motivation 
to streamline safety reporting. 
Limitations in safety reporting in the premarket setting are widely recognized. Clinical 
research professionals note inefficiencies in reporting requirements that may lead to “reporter 
fatigue” and “reporter bias” seen in AE reporting in medical publications in general, and in 
oncology trials in particular (164, 165). Reliability of toxicity rates is further limited in the pre-
marketing setting, since safety reports are submitted on an individual basis rather than in aggregate. 
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When submitted in aggregate, safety data are analysed as tabulations of severe or Grade 3-4 all-
causality AEs, and some categories may not be equally informative with regard to product safety 
(166). Other measures of tolerability such as drug interruptions and discontinuations or dose 
reductions, may not be captured, nor are patient reported outcomes (PROs) (167-169), as will be 
discussed further below. Healthcare utilization (hospitalizations, concomitant medications) 
administered to treat toxicity could be better documented. Finally, a well-described limitation of 
pre-market data is that trial populations are often younger or healthier than those with the disease 
in the general population (170). Gaps in our understanding of a product’s safety and tolerability at 
the time of approval behoove us to enhance post-marketing surveillance to complement other 
safety and tolerability assessments and better understand the product’s use in a real world 
population, as discussed below and in the next subsection 
Safety Review of a Submitted Marketing Application  
The standard required for approval across regulatory agencies is demonstration of safety 
and effectiveness. The safety analysis that informs the risk-benefit assessment relies heavily on 
the use of tabulated rates of severe and/or high-grade AEs, with some weight given to dose 
interruptions, discontinuations, and reductions. Increasingly, approval is granted on the basis of 
surrogate endpoints collected earlier in the drug development process (accelerated approval (AA) 
in the US, conditional marketing authorization (CMA) in the EU, conditional and term-limited 
approval in Japan etc.), allowing earlier patient access to promising new therapeutic agents (171, 
172). Approval based on endpoints occurring well before death results in shorter duration of 
administration and follow-up than is seen in randomised trials using survival endpoints. Unlike 
many cytotoxic agents given intermittently and for relatively short durations, toxicities seen with 
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chronically administered targeted agents can vary in onset, duration and character based on 
mechanism of action as detailed in prior subsections. Adverse drug reactions may be idiosyncratic 
or related to cumulative toxicity, but in either case the shorter trial duration and follow-up that is 
characteristic of approvals using expedited regulatory pathways limits characterization of the 
intermediate and long-term safety profile for these agents. Furthermore, the predominance of 
single-arm trials using expedited pathways challenges accurate attribution of an AE to the therapy. 
This is particularly problematic in haematology-oncology, where differentiating AEs related to the 
cancer or other comorbidities from those that are potentially drug related is challenging.   
To mitigate these uncertainties, regulatory agencies leverage post-marketing 
pharmacovigilance and clinical studies. FDA has authority to require (post-marketing 
requirements, PMRs) or request (post-marketing commitments, PMCs) further studies to better 
characterize safety following the approval of a drug.(173) These studies assess or identify a serious 
risk(s) related to the use of a drug, but are subject to the same challenges noted above regarding 
toxicity reporting in clinical trials. TGA also mandates standard and non-standard post-marketing 
requirements following approval, and PMDA can mandate post-marketing investigations during 
the re-examination period under the Pharmaceuticals and Medical Devices Act. At the time of 
finalizing a procedure or in follow-up of a signal evaluation, the EMA’s Committee(s) may agree 
that the applicant/marketing authorization holder (MAH) should provide additional data post-
authorization, including additional pharmacovigilance activities.  
Efforts to Improve Safety Reporting and Review: Pre-market Setting and Submission Review 
International regulatory bodies have begun to address impediments to efficient and 
informative safety data capture. Many issues stem from incomplete reporting or uninformative 
Final author’s draft of a paper accepted for publication in the Lancet Haematol 12 Jun 18 doi: 
10.1016/S2352-3026(18)30051-6. 
63 
 
over-reporting. An expanded toolbox of electronic submission, capture, and analysis of toxicities 
could improve these deficiencies. The current manual reporting/submission systems and region-
specific variations on regulatory requirements for reporting toxicities, coupled with an often 
conservative interpretation of the regulatory requirements by sponsors, has led initial efforts to 
focus on decreasing the number of safety reports submitted (174-176).  The risk of missing genuine 
safety signals due to a large volume of irrelevant information is real, and extraneous data should 
not be submitted.  
To improve efficiency of safety report submission, TGA has implemented a shift from 
lengthy paper submissions to a single-page online submission. In Japan, safety reports of industry-
sponsored registration trials are electronically submitted to PMDA based on the International 
Conference of Harmonisation (ICH) E2B. FDA recently completed a pilot whereby OHOP, in 
collaboration with the Office of Surveillance and Epidemiology (OSE), evaluated the feasibility 
of submission of safety reports in the pre-marketing setting as datasets, which can then be 
processed for analysis. The results provided a technical framework for digitized submission of 
premarket safety reports based on existing standards used in the post-marketing setting via FDA’s 
Adverse event Reporting System (FAERS) (177). The project is in its second phase of 
implementation, which aims to build this as a standard agency process for premarket safety 
submissions. Once the efficiency of submission and collection is addressed, the breadth of 
information to be captured needs to be outlined. In the EU, sponsors report SUSARs to Member 
States as well as the centralized EVCTM; these reports are accessible to all Member States in the 
European Economic Area (EEA) for further analysis. Non-commercial sponsors can use the 
EudraVigilance web-interface (EVWEB) to electronically create and submit SUSAR reports, and 
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the EudraVigilance system is used to manage and analyse information on suspected adverse 
reactions in the pre- and post-authorisation phase.  
Legislation has been advanced to support incorporation of the patient experience into drug 
development (21st Century Cures Act;(178) EMA Appendix 2 to the Guideline on the evaluation 
of anticancer medicinal products in man (179)). One area of great interest to the drug development 
community is the use of patient-reported outcomes (PRO) to complement clinical AE evaluation. 
This topic is comprehensively discussed in Subsection II. Collection of PROs should be 
methodical, addressing the limitations of missing or biased data that hinder application of 
statistical rigor, yet should not present a burden to patients (118, 180). PRO may assist in capturing 
low grade, potentially burdensome side effects that are unlikely to be the basis for non-approval 
of a therapy, but can provide important information to add to the overall benefit-risk assessment, 
particularly in the evaluation of a drug that has similar efficacy to an available therapy, but that 
may have a more favourable toxicity profile.  
Incorporating PRO data to better inform the safety and tolerability of a therapy will require 
improving acquisition and standard submission of datasets.  Leveraging the benefits of electronic 
methods are critical for the practical integration of PRO data into the regulatory review process. 
Prolonged assessment and careful documentation of supportive care medication use, 
hospitalizations, and other healthcare utilization can provide additional complementary safety data 
informing tolerability. Methods to analyse and visualize PRO data and other patient outcomes to 
inform treatment tolerability are active areas of research addressed in Subsections I and II. FDA 
and other international regulatory and healthcare policy leaders are collaborating with experts in 
the healthcare outcomes research field to explore ways in which this data can assist regulatory 
review and inform product labeling.(86, 89, 181, 182)  Incorporation of PROs, as well as 
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assessment of the time course and severity of symptomatic AEs to inform tolerability, into labeling 
has begun at a very early stage. PROs are integral in TGA’s decision-making process, using the 
adopted EMA guidelines referenced above. In the US, certain chronically administered products 
such as those targeting the PD-1/PD-L1/2 pathway include not only tabulated summaries of 
clinician-reported AEs and their severity, but also the median time to onset of immune-mediated 
toxicities (nivolumab, pembrolizumab, and avelumab package inserts). The approval of crizotinib 
for a subset of locally advanced or metastatic lung cancer patients included PRO information that 
added important complementary material to clinician-reported incidence of vision disorders.(183) 
In response to PRO assessments, patients reported the onset of visual disturbance within the first 
week, occurred 4-7 days per week, and lasted up to 1 minute with mild or no impact on daily 
activities. As collection and analysis tools are better refined, regulatory agencies agree that 
incorporation of these data into the review process is critical to better describe safety and 
tolerability. 
Additionally, patients or their advocates can inform drug development during the trial 
design stage. The FDA Patient Liaison Program, through its Patient Representative Program and 
other initiatives (78), and the Professional Affairs and Stakeholder Engagement (PASE) initiative 
in the Center for Drug Evaluation and Research (CDER) (107), incorporate opportunities for 
patient and advocate involvement in the review process.   
Post-marketing Pharmacovigilance:  Tools for Moving Forward 
The post-marketing setting provides an opportunity to gain important additional 
information on safety and tolerability of cancer therapies. While post-marketing data may benefit 
from flexibility and larger sources of data in a broader generalized population, these data are less 
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controlled, adding uncertainty outside the rigor of clinical trials (Figure 10). Safety data may be 
generated from off-label use of approved products by individual practitioners. Off-label 
prescribing of drugs and biologics is beyond the authority of FDA and not regulated by TGA, 
although there remains an AE reporting requirement; lack of insurance coverage may limit this 
practice with increasing drug costs (reference financial toxicity subsection) but not entirely. In 
other countries where approval and coverage are more closely linked, off-label use is more limited. 
Nonetheless, once a drug has been approved, it is used in a wider population that may be older, 
sicker, and with different disease and patient characteristics than those enrolled on clinical trials 
(184). Furthermore, the duration of therapy may be longer than that of the patients on trial.  
Collection of data post-marketing can document long-term toxicities and tolerability, 
including low-grade toxicity over time and is mandated by some regulatory agencies. In Australia, 
TGA mandates a 3-year period of post-marketing surveillance update reporting, which enhances 
assessment of cumulative toxicities of chronically administered products. An “Enhanced Post-
Marketing Monitoring and Analytics” (EPMMA) Project is being implemented, using a number 
of IT solutions to enhance TGA’s ability to identify and manage risk associated with post-market 
activities, including electronic submission of AE reports.  
FAERS in the US is the main venue for submission of post-marketing safety information 
by healthcare providers, patients and other stakeholders, via the product manufacturer or directly 
to FDA MedWatch. FAERS is also subject to limitations of reporter fatigue and bias described 
above in the pre-approval setting. In May 2008, the FDA also launched the Sentinel initiative, 
which allows the Agency to “access information from large amounts of electronic healthcare data, 
such as electronic health records (EHR), insurance claims data and registries, from a diverse group 
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of data partners.(185) These de-identified data can then be queried for analysis of safety 
signals.(186)  
In Japan, the Pharmaceuticals and Medical Devices Act prescribed re-examination period 
is 10 years for orphan drugs, 8 years for new molecular entity drugs, and 4 or 6 years for the other 
drug applications.  PMDA has constructed the medical information database “MID-NET,” where 
EHR data, claims data from the national health insurance system and hospital inpatient expense 
data are stored. Since 2016, Japan has piloted use of this system for safety data, and they plan to 
implement full-scale utilization in 2018. Signals detected through any of these systems can be used 
to revise the package insert if assessed as necessary.  
In the EU, the Good Pharmacovigilance Practices (GVP) provide guidance on the reporting 
of suspected adverse reactions for authorized medicinal products (GVP Module VI) includes 
special situations such as off-label use. These reports are submitted to EudraVigilance, and thus 
accessible to all national Competent Authorities (NCA) in the EEA for signal detection and 
evaluation. As of the 22nd of November 2017, marketing authorisation holders will also obtain 
access to EudraVigilance, to the extent necessary to comply with pharmacovigilance obligations. 
This includes the EudraVigilance Data Analysis component, where companies will have access to 
all reports related to active substances for which they hold a marketing authorisation in the EEA. 
Additionally, the IMI WEB-RADR project developed a mobile app for patients and healthcare 
professionals to report suspected adverse reactions to the respective national NCA. This mobile 
app was trialed in three Member States with plans for further rollout and enhancement for two-
way communication to provide feedback related to medicines for which reports were submitted.  
Opportunities to leverage various types of real-world data to inform post-marketing safety 
exist in resources such as Sentinel, ASCO’s CancerLinQ(187), FLATIRON, Optum, OPeN, 
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disease-specific patient registries, patient-generated data platforms (e.g. Inspire, PatientsLikeMe, 
others), ORIEN, large big data consortium projects in haematology like IMI2 HARMONY and 
other collaborative efforts (GNS Healthcare and the Multiple Myeloma Research Foundation, 
Biogen Idec and Columbia University Medical Center), public and private claims databases, 
institutional data bases and others. Large big data consortium projects that are integrating and 
analysing anonymous patient data from a number of high quality sources may provide important 
learnings on outcomes in haematological malignancies as well as support decision making of 
patients, policy makers and clinicians. As described in Subsection VI, the fact that most records 
exist in text form (unstructured) presents a challenge to ingestion and aggregation of real-world 
data. 
Recognizing this challenge, and that big-data analytics in other fields may be borrowed for 
these purposes, FDA’s OHOP, together with the US Department of Health and Human Services’ 
(DHHS) Innovation, Design, Entrepreneurship and Action (IDEA) laboratory, launched the 
Information Exchange and Data Transformation (INFORMED) initiative. This aims to expand and 
maintain an infrastructure for haematology-oncology data science and big-data analytics, as well 
as to support systems thinking in haematology-oncology regulatory science research; specifically,  
to devise and use solutions that will improve efficiency, reliability, and productivity (185). The 
initiative includes recruitment of experts in big-data analytics, the technical infrastructure itself, 
mentorship and educational support, and stakeholder engagement. How the data obtained through 
this initiative will be analysed and interpreted requires much thought and consideration, but the 
potential to broaden data capture addresses many of the current limitations to toxicity assessments 
discussed above. FDA has presented results from a collaboration with Flatiron Health that analysed 
whether patients treated with agents that were approved for use with a companion-diagnostic were 
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tested (188). A collaboration between FDA and CancerLinQ (CancerLinQ is further described in 
Subsection VI) is underway to allow for the collection of RWE when drugs are approved for a 
specific population; this evidence may potentially inform labeling changes or using data obtained 
from a real-world population. Although the initial focus is on a non-haematologic malignancy 
(melanoma) and the various immune and targeted therapies used in its treatment, similar 
approaches in haematologic malignancies are certainly relevant.  
As familiarity is gained with how these systems work and how they need to be improved, 
they may at minimum afford increased data capture in the clinical trial setting. OHOP/OCE 
envisions the potential for “novel pipelines” of data, including real-world data, to be submitted as 
part of a marketing application and taken into account during regulatory decision making (189). 
The ability to harness these capabilities through pragmatic real-world trials would allow for a 
robust assessment of intervention outcomes in the broader population outside the traditional 
clinical trial context (190-192). The ultimate ability to collect real-world data in or out of the 
context of a  clinical trial and allow for labelling that better reflects the population to be served 
while retaining the rigorous standards for protection of patient safety is a topic debated in the 
regulatory community (193). FDA uses real-world evidence garnered electronically for regulatory 
decisions related to safety; data obtained through FAERS has been used to trigger safety labeling 
changes initiated by the Agency.  This evidence may be the only pragmatic approach at this time 
to answering questions that often remain at the time of drug approval regarding the optimal dosing 
regimen, long term use, outcomes in subpopulations, and others (194). 
The traditional method of AE reporting and analysis has served drug development well for 
decades, but focuses on detection of extreme safety signals such as death and severe morbidity. 
An opportunity exists to build on past experience using novel tools and technologies and improve 
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regulatory assessment of AEs in haematologic malignancies both pre and post-marketing (see 
Table 10). A more efficient process that is less time consuming and expensive will include 
instruments and analytics that reflect tolerability using PROs and other clinical outcomes, 
platforms to integrate all available data from trial participants and real-world patients alike, and 
analytics to interpret these data. Ultimately, these are fundamental to the goal of robust collection 
of relevant toxicity data that can be extrapolated to a broad population of patients and used to 
inform drug development, approval, and treatment decisions. 
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Subsection VI:  Toxicity Reporting in Haematologic Malignancies in the Real World 
Setting 
 
Drug toxicity is established in clinical trials where standardized and detailed AE (AE) data 
are collected prospectively and provide a solid foundation for the initial benefit-risk 
characterization of new anticancer drugs.  So why should we care about real-world evidence with 
incomplete registrations, insufficient follow-up, biased data, caveats of retrospective causality 
assessments, and little information on drug dosing schedules? Subsection V explored some aspects 
of post-marketing surveillance of AE from a regulatory standpoint.  This section expands upon the 
importance of toxicity data collected outside of clinical trials, explores the potential returns from 
improvements in AE assessment and reporting in haematology, and identifies opportunities to 
enhance this valuable resource in the real world setting. 
Collection and documentation of toxicity data in routine clinical practice 
In routine clinical practice, it is impractical to perform the detailed toxicity assessments 
required in clinical trials. Effective treatment of a haematologic malignancy generally takes 
priority over AE assessments outside of clinical trials, particularly when a treatment is used within 
its approved indication. Occurrence of AEs are documented in health care records if patients 
disclose their experience and/or the treating healthcare provider interprets symptoms/findings to 
be consistent with an adverse drug reaction, and relevant enough to merit their documentation. 
Patients may minimize or omit some AE for fear of treatment modification or termination.  Even 
when aware of serious AEs, health care professionals only report a small fraction to the health care 
authorities responsible for conducting pharmacovigilance.(195) Thus, real-world toxicity data is 
Final author’s draft of a paper accepted for publication in the Lancet Haematol 12 Jun 18 doi: 
10.1016/S2352-3026(18)30051-6. 
72 
 
likely more underreported than in clinical trials. Agreement between the perception of a particular 
AE between patient and clinician is only moderate, again suggesting a bias in AE reporting by 
clinicians.(196) These factors represent serious limitations to the use of real-world data for toxicity 
assessment. 
Role of databases and registries in AE collection 
Much of what has been learned about toxicity in real world patients is drawn from several 
registries and databases that were originally designed to capture data for administrative purposes 
and/or outcomes research.(197, 198) A few examples of databases are the Surveillance, 
Epidemiology, and End Results (SEER) Program which covers approximately 28% of the 
American population, Mayo Clinic / University of Iowa MER/SPORE hospital based patient 
cohort, the regional British Columbia Centre for Lymphoid Cancer database covering lymphoma 
patients in the westernmost province of Canada, and national Danish and Swedish registries for 
several haematologic malignancies.(199-205) Validation studies have shown high quality of data 
in terms of accuracy and good database coverage for some of the databases.(203, 206) Registries 
and databases are potentially valuable resources for AE studies in a real-world patient population, 
although detailed toxicity data are typically not entered prospectively, as this is not the main 
purpose of these databases. 
At a basic level, databases can be used to identify consecutive patients treated during a 
given time period, with subsequent back-tracking in medical records for AEs. They can also be 
used to identify a relevant patient cohort for a prospective analysis, as done in a Norwegian study 
of patients treated with autologous stem cell transplantation over a period of 20 years. 
Echocardiography of participating survivors revealed a higher than expected rate of left ventricular 
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systolic dysfunction.(207) These approaches add evidence for or against safety signals from other 
prospective or retrospective reports and provide the denominator of exposed patients needed to 
estimate the frequency of a particular AE. In countries like Denmark and Sweden, unique 
identification numbers for each individual inhabitant combined with nationwide patient registries 
that capture information on hospital contacts enables nationwide toxicity studies. As an example, 
a Swedish study showed that patients surviving Hodgkin lymphoma following contemporary 
treatment had increased healthcare use compared to the general population during the first decade 
post-diagnosis, reiterating the burden of late toxicities in Hodgkin lymphoma survivors.(208) 
Again, these analyses are limited to AEs that consistently require hospital contacts.  
Relying on retrospective data collection mandates clear, consistent documentation of AEs 
based on consensus definitions in medical records and insensitivity to interpretational bias. 
Fatigue, insomnia, neuropathy, and pain are common symptoms among cancer patients with 
profound negative impact on quality of life, but these subjective toxicities are not reliably assessed 
in retrospective studies.(209) In these situations, absence of documentation cannot be taken as 
evidence of absence of the AE. As many patients with haematological malignancies become long-
term survivors or take drugs continuously over months to years to control their disease, AEs that 
are not life threatening but nevertheless have a negative impact on quality of life become 
increasingly important. Indeed, quality matters as much as quantity of life to many cancer patients 
and data collected prospectively from real-world patients may better inform this difficult 
balance.(210)  
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The value of real-world toxicity data 
Despite these limitations, there is significant value to real world toxicity data (Table 11) 
as well as evidence collected and reported by patient organisations in their constituency on real-
world side effects.  First, only a small proportion of cancer patients (<3% in the US) are treated 
within clinical trials due to restrictive inclusion criteria and limited availability of clinical 
trials.(211) Patients volunteering for clinical trials are typically younger, have better performance 
status and fewer comorbidities than unselected real-world patients, even in settings where the 
majority are enrolled in a clinical trial.(212-214) More importantly, clinical trials protocols often 
exclude a large proportion of potentially eligible patients on the basis of baseline organ function, 
comorbidities including chronic infections, multiple concomitant medications with possible 
interactions, and certain prior therapies.  This limits extrapolation of clinical trial results to real-
world patients, particularly in situations of off-label use, and can lead to greater toxicity in clinical 
practice than initially anticipated from clinical trials.(215) For example, patients with 
relapsed/refractory Hodgkin lymphoma previously treated with allogeneic stem cell 
transplantation were excluded from the initial phase I/II trials of immune checkpoint 
inhibitors.(216) Real-world data subsequently described a 30% incidence of acute graft versus host 
disease in patients treated with nivolumab for relapse after allogeneic stem cell transplant, 
providing important practice-informing data.(217) 
Second, follow-up in prospective trials often becomes reduced when the study meets its 
primary endpoint, limiting the detection of uncommon or late AEs.  The discovery of fatal 
progressive multifocal leukoencephalopathy from JC polyoma virus reactivation in rituximab-
exposed patients exemplifies the value of real-world data for post-marketing 
pharmacovigilance.(10) Third, the rapidly expanding number of drugs for haematological 
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malignancies with some patient groups receiving several lines of treatment underscores the 
necessity of collecting real-world data that can be used to analyse drug interactions and cumulative 
toxicities. Many of these agents will be used in sequence or combination, and real world data may 
inform whether prior exposure to a particular treatment increases toxicity from the next line of 
therapy. 
 
Finally, databases can validate signals from other sources with excellent statistical power.  
For example, Chen et al estimated the incidence of heart failure or cardiomyopathy in 45,537 older 
women receiving trastuzumab-containing chemotherapy for early breast cancer using the SEER 
database.(218) In addition to confirming the results of randomized clinical trials in a general 
population (this study suggested the incidence of cardiac dysfunction may actually be greater in a 
population of older women), the study evaluated this particular toxicity endpoint within a sample 
size that would never have been possible in the context of prospective clinical trials.  Table 11 
summarizes the strengths and limitations of databases for the assessment of toxicity. 
Enhancing AE reporting in databases: lessons from clinical trials 
The most obvious way of integrating toxicity data into existing databases is to treat AEs 
similarly to other variables already being routinely collected and entered.  However, there is more 
to the process than simply adding new fields for data entry.  The main challenge with toxicity is 
the data itself: many toxicity endpoints are not necessarily objective or easy to measure, 
introducing subjectivity in the retrospective categorization of toxicity. AE reporting in clinical 
trials is typically based on the Common Terminology Criteria for Adverse Events (CTCAE), which 
provides standardized terminology for AE classification and its associated severity. Ideally, real 
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world data should be collected with similar consistency, but this is not feasible in a routine clinical 
setting. However, the principles of collecting toxicity data systematically, objectively, and at 
multiple points over time can certainly be applied to real world databases. 
The main objective of database enhancement is to capture the clinically significant 
toxicities in a large population of patients.  Therefore, the process of data ascertainment should not 
need to be as exquisitely detailed as in clinical trials. Also, increasing complexity will increase 
resource utilization and cost. Because it would be impractical and resource-intensive to capture 
every single possible AE for every single patient, some databases could choose to limit their focus 
to certain patient groups and/or toxicity categories.  One example is to focus exclusively on 
potentially curable haematologic malignancies where toxicity could derail the success of curative 
therapy.  Another example is to collect a range of predetermined AEs that are felt to be most 
relevant for a given group of patients, although this approach risks missing important unexpected 
toxicities.  Finally, many administrative databases capture “sentinel events” (i.e., emergency room 
visit, hospital admission, discontinuation or change of prescription, death) which are more 
objective than many of the toxicity outcomes. This may be a more efficient alternative to screen 
for the most serious toxicity, but ultimately requires going back to individual medical records. 
The CancerLinQ, a physician-led ASCO initiative, is an example of a learning system for 
oncology that will offer new opportunities to explore real-world toxicities in large groups of 
patients(187). It was primarily developed to improve quality of care for patients treated in a routine 
clinical setting by providing real-time analyses of real-world data directly to the responsible 
physician to facilitate more well-informed decisions.(219) By collecting data directly from 
electronic health care records, CancerLinQ obviates the need for manual data abstraction, which 
makes it attractive to clinicians outside academia and ensures fast collection of large amounts of 
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longitudinal data. However, the system relies on data documented in electronic records and 
therefore shares some of the limitations discussed above.(220)  
Another lesson from clinical trials is that toxicity is best assessed prospectively and in real 
time, when there may be an opportunity to query the clarity of the data, obtain additional 
information about a particular AE, or perform real-time checks for emerging toxicity signals.  
While this may be feasible in databases such as CancerLinQ, other resources such as the large 
national databases/registries would not be able to accommodate these requirements without 
substantial investments.  
The patient perspective on toxicity reporting 
Health care professionals typically collect data to objectively measure frequency and 
severity of AEs, but each patient has a unique experience of AEs in the context being diagnosed 
with cancer and expecting a clinical benefit from treatment. Although this experience is difficult 
to quantify, they need be accounted better for in future studies of real-world patients. As an 
example, grade 3 neuropathy may be an acceptable tradeoff for a lymphoma patient receiving 
curative intent treatment, whereas it may not in an elderly myeloma patient with postural instability 
receiving palliative treatment. Important elements that influence treatment decisions from a 
patient’s perspective are goal of treatment (curative versus palliative), magnitude of clinical 
benefit, potential toxicities, personality, and socioeconomic factors.(210, 221) In metastatic 
colorectal and lung cancer, patients’ expectations about effects of chemotherapy were studied in 
1,193 individuals and the majority of patients had not fully understood that chemotherapy was 
unlikely to cure their disease.(222) Misconceptions of treatment goals alter the ability to make 
informed decisions regarding treatment and probably also influence the subjective experience and 
acceptance of associated toxicities. Thus, to fully understand the severity of toxicities as 
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experienced by the patients and their impact on quality, we need obtain toxicity data from patients 
fully realistic about the magnitude of clinical benefit from a treatment. Patient organisations are 
also ideally positioned and increasingly engaged to collect and report real-world evidence on side 
effects based on data gathered from their constituency. (77) 
Taking advantage of the patient experience to guide AE management 
Real world AE data can also be enhanced by directly involving patients in the toxicity 
reporting process. The data generated by transferring the actual reporting to patients themselves 
could provide a better perspective on the aspects of toxicity that patients, rather than healthcare 
providers, find most relevant. As explored earlier in this article, the implementation of tools that 
measure patient reported outcomes (PRO) is possible today with the broad availability of mobile 
devices and obtaining such data in a large scale would improve knowledge about real-world 
toxicity substantially. As technology improves and becomes more widespread, as the aging 
population becomes more comfortable with technology, there are opportunities to enhance toxicity 
reporting with tools such as PROs. A consensus PRO system, such as the PRO-CTCAE discussed 
in Subsection II, that can summarize and quantify the wealth of information entered by the patient 
into clinically useful information has the potential to better describe real world patients’ symptoms, 
the impact of a particular symptom control intervention, and track progress over time.(61, 223) 
Figure 11 outlines a process for optimizing databases for future toxicity studies with integration 
of genomic data and PRO measures. 
Ultimately, clinical trials do not describe the entire picture of the toxicities of a particular 
treatment.  Real-world data on toxicity are an important addendum to these data, and constitute a 
resource that has not yet been exploited to its full potential. Many of the existing databases and 
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registries can be harnessed to capture toxicity, but to maximize the clinical and research value of 
real-world toxicity data, consistency and standardization procedures similar to those used in 
clinical trials should be applied. Initiatives like CancerLinQ that data mines electronic health care 
records provide new opportunities for big data analyses of longitudinal data, but cannot stand 
alone. Incorporation of PROs and integration of genomic and clinical data are initiatives that may 
better clarify the impact of AEs on the lives of patients. These initiatives will involve a significant 
investment that will hopefully pay off with improved patient experiences and outcomes. 
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Subsection VII: Financial Burden of Therapies for Haematologic Malignancies 
In this Commission dedicated to AEs faced by patients with haematologic malignancy, it 
is important to recognize that the adverse effects of a cancer diagnosis and cancer therapy extend 
beyond the physical and psychological impacts of the disease and treatment. The social and 
financial effects of cancer, cancer treatment, and supportive care on the patient, family, and other 
care providers can profoundly influence the lives of patients and families worldwide.(224)  
“Affordability” and “sustainability” are practical terms with pragmatic meaning at an international 
level.(225)  Although the cost of cancer drugs is numerically highest in the US, which accounts 
for 46% of the global oncology market, evidence suggests that when compared against the per 
capital purchasing power, drugs are most unaffordable in middle income nations.(226) 
The costs of cancer care also can have broad reaching effects on cancer patients, providers, 
health care delivery systems, payers, and society. From the perspectives of society and payers, the 
costs and benefits of cancer therapies have been extensively studied.(227-236) While certain novel 
therapies have been associated with favorable cost effectiveness profiles across a series of studies 
such as rituximab(233, 234, 237) other agents such as bevacizumab in colorectal and lung cancer 
have less favorable profiles.(235, 238, 239) One recent report used a common framework to 
examine the cost-effectiveness of the addition of bevacizumab to first-line chemotherapy for 
metastatic colorectal across five countries demonstrating large differences in cost-effectiveness 
between countries.(240) Similar approaches will be needed to understand the value and financial 
impacts of drugs for haematologic malignancies from the societal perspectives across multiple 
international payers. However, even drugs that produce remarkable benefits for patients with 
haematological malignancies such as ibrutinib and imatinib are associated with substantial 
financial burden to patients and society.(241, 242)  Moreover, as in the case of imatinib, the price 
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of the medication is continually escalated over time, reducing the value of past cost-effectiveness 
calculations for making present decisions.(243)  Although the financial burden associated with a 
treatment strategy can be more difficult to assess that treatment toxicity associated AEs, it has 
substantial impact on patient well-being and existing Emerging tools, such as the recently 
described affordability index(244), can be applied to quantify this impact. 
The rising costs of cancer therapies 
The cost of treating cancer continues to rise to unprecedented heights. Studies in both 
haematologic malignancies and solid tumors have demonstrated both the rising prices of new 
cancer drugs over time as they enter the marketplace and increases in post-launch prices over time 
for orally administered anticancer drugs following approval by the FDA in the US.  Even in 
situations where competition exists in the marketplace or older agents become open to generic 
manufacturing, drug prices have remained high or increased at rates higher than new agents.(242, 
245)  For example, imatinib has revolutionized the care of patients with chronic myeloid leukaemia 
(CML), transforming CML from a disease associated with poor outcomes in 2001(246) except 
with stem cell transplantation to one that is currently managed as a chronic disease with excellent 
outcome with oral therapies.(247) Surprisingly, although imatinib cost USD $26,000 per year in 
2001, its price rose steadily by 10-20% per year until it reached a maximum of USD $146,000 per 
year before going generic.(248)  Other studies identify that inflation-adjusted per patient monthly 
drug prices increased by 5-12% per year during the period from 2007-2013.(249, 250) Contrast 
these price increases with real household income in a nation, such as the US, which has remained 
stagnant for decades.(243)  For this reason, some authors conclude that policy makers who wish 
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to reduce the costs of anticancer drugs must develop approaches that affect prices long after the 
drug has reach the market as well as immediately following regulatory approval. 
One approach to the latter problem has been to estimate a value based price for new a 
cancer agent prior to FDA approval.(251) An analysis to establish value-based pricing for an agent 
links the price of a drug to the benefit that it provides. This value-based pricing model will be 
tested in the US in practice with the roll out of the first in class CAR-T therapy, tisagenlecleucel, 
which bears a list price of USD $475,000.(252)  A partnership with Centers for Medicare & 
Medicaid Services in the US to allow for payment only when patients respond by the end of the 
first month(253).  Broader applications of approaches to circumvent the financial burdens of new 
cancer drugs will require establishing value based frameworks for cancer care.(254-257) Other 
strategies have been proposed to address the dramatic rises in cancer drug prices although these 
will involve tradeoffs.(258) An application of this approach to diffuse large B-cell lymphoma 
(DLBCL) examined the potential cost-effectiveness of DLBCL subtype testing and providing 
targeted therapies for activated B-cell-line (ABC) DLBCL.(259) These authors showed that a 
subtype-based approach demonstrated a favorable incremental cost-effectiveness ratio when 
compared with administering standard therapy (R-CHOP) to all patients regardless of subtype. 
They also explored the range of scenarios varying test type (immunohistochemistry vs. gene 
expression), test sensitivity and specificity, and therapeutic benefit for a novel approach to provide 
benefit for ABC patients. Such an approach can help to identify where subtype-based treatment 
strategies and novel therapies remain cost-effective and can reduce financial burden, thereby 
informing the design of phase 3 trials that are needed to validate model findings and draw definitive 
conclusions.  
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Modern approaches to drug discovery and development have dramatically increased the 
number of targets for cancer therapies. The advent of these agents presents a challenge in terms of 
timeline for drug development and healthcare costs. Overcoming the rising cost of cancer drugs 
may also require new pricing and payment systems and several approaches have been suggested. 
Recent approach for delivering cost-effective care and determining the costs of drugs and services 
for cancer care include: bundled payments,(260) indication specific pricing,(261) payment by 
results,(262) third party buy and bill,(263) pathway adherence,(263) and value based pricing.(264, 
265) and inclusive shared savings.(266) In addition, new strategies are needed to support patient 
selection and allocation for clinical trials, guideline development, and payer coverage 
determination to identify individuals and populations most like to benefit from a particular therapy. 
These approaches should address clinical value in addition to statistically significant clinical 
benefit, and will be necessary to guide delivery of high value interventions to our patients. 
The impact of cost of care on the cancer patient 
While discussions about the costs of cancer supportive care commonly focus on balancing 
the potential to save and extend lives against the costs to society or payers, out-of-pocket expenses 
incurred by patients for accessing care can range widely and can impact patients’ financial well-
being significantly and are considered by some as an “adverse event” given the resultant impact 
on a patient and family and worthy of grading on similar scales as any other AE.(267, 268) Out-
of-pocket costs include any payments for medical care that involve costs not covered by health 
insurance. Types of out-of-pocket cancer care costs include: lodging/travel for medical care; 
deductibles that are paid for medical care before a health insurance plan begins payments; 
copayments for each healthcare service such as a doctor appointment or prescription; and 
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coinsurance, which is the percentage of costs an individual pays for a service in concert with the 
health insurance plan. 
Cancer patients undergoing therapy and cancer survivors commonly report higher out-of-
pocket spending than people who have not had cancer. Out-of-pocket expenses may be particularly 
pertinent in circumstances without universal healthcare coverage or for uninsured or poor 
individuals for whom cancer care is one of several financial burdens. Over one third of patients 
with multiple myeloma reported taking a variety of steps to help cover medical costs, including 
pharmaceutical assistance programs, depleted savings accounts, or borrowing from retirement 
savings.(269) A cross-sectional pilot analysis of financial toxicity in multiple myeloma has found 
three factors associated with treatment-related financial hardship: younger age, non-married status, 
and lower annual household income.(270) It has been estimated that 40-85% of cancer patients 
stop working during initial treatment, with absences ranging from 45 days to nearly six months 
and cancer survivors may contend with long-term health barriers that limit return to work after 
treatment. (271) Consequently, because cancer treatment can affect an individual’s ability to work 
and pay household bills, financial hardship from cancer therapy more commonly affects patients 
who are the primary or only wage earner for the household; individuals with significant debt or 
limited assets before the cancer diagnosis, and people with inadequate health and disability 
insurance.  
Cancer survivors also may have financial problems many years after they are diagnosed 
because they may be paying for ongoing management of late effects. Since many more individuals 
live longer after an initial diagnosis of haematologic cancer and some patients continue chronic 
oral therapy or intermittent administration of serial therapies at relapse out-of-pocket expenses 
may become even more significant for cancer survivors and their families who face recurring and 
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continuing costs over many years. One study examined the economic burden of oral therapies for 
the treatment of patients with chronic lymphocytic leukaemia (CLL).(241) Although novel oral 
therapies for CLL such as ibrutinib, idelalisib, lenalidomide, and venetoclax have facilitated 
treatment administration, reduced toxicity, and improved outcomes particularly for older patients 
with CLL, their high cost has raised concerns about affordability and the financial burden to 
patients and society. The authors utilized a simulation model to project the future prevalence and 
cost burden of CLL in the era of evolving management of CLL with oral targeted therapies from 
2011 to 2025 where: chemoimmunotherapy was the standard of care before 2014, oral targeted 
therapies were administered for patients with del(17p) and relapsed CLL from 2014, and for first-
line treatment from 2016 onward. Utilizing disease progression and survival data for each therapy 
based on published clinical trials the authors projected that the per-patient lifetime cost of CLL 
treatment would increase from USD $147,000 to $604,000 (310% increase) as oral targeted 
therapies become the first-line treatment. The corresponding total out-of-pocket cost was projected 
to increase from USD $9,200 to $57,000 (520% increase). High cost of care associated with oral 
and other novel therapies now and in the future can have a substantial impact on patients, their 
caregivers, and patient outcomes. 
The impact of financial hardship on patient outcomes 
For some patients the high costs of care may lead to refusal of treatment or nonadherence 
to recommended treatments and poorer clinical outcomes.(272-274) In one recent analysis based 
on insurance claims data, higher out-of-pocked costs were linked with high rates of oral 
prescription abandonment and delayed initiation across a variety of different malignancies.(275).  
At the extreme, financial hardship following a cancer diagnosis has been associated with increased 
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risk of filing for bankruptcy.(267) One study linked data from a population-based cancer registry 
from Western Washington that is part of the National Cancer Institute’s Surveillance 
Epidemiology and End Results Program (SEER) and a randomly sampled age-, sex-, and ZIP 
code–matched population of people without cancer with federal bankruptcy records for the period 
1995–2009.  This study found that cancer patients had a rate of bankruptcy that was 2.65 times 
higher than people without cancer.(267) For cancer patients who experience an extreme form of 
financial toxicity such as bankruptcy, these financial effects can be associated with increased 
mortality. (276)  Thus, at the extremes it is clear that the financial hardships that cancer care can 
impose can impact patient outcomes. 
Measuring the financial impact of cancer care within clinical trials 
One of the most challenging aspects of evaluating the financial impact of new cancer 
interventions is determining the appropriate measures associated with providing care. The large 
number of possible measures of financial toxicity, have been categorized into 3 broad areas: 
monetary measures defined by out-of-pocket expenses or the ratio of out-of-pocket expenses to 
income; objective measures in assessing debt levels, the need to borrow money from family or 
friends, sell assets, withdraw money from retirement or savings funds, and filing for bankruptcy; 
and subjective measures on perceptions of cancer-related financial burden. Each approach 
measures a different aspect of financial hardship. All three measures should be assessed in clinical 
trials and in observational studies where possible to provide comprehensive assessment of the 
financial impact of therapies on patients with haematological malignancies. 
When monetary measures are used, clarifying the perspective of who is paying for the costs 
is an important consideration.  The United States Panel on Cost-Effectiveness in Medicine 
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recommends that healthcare costs be determined from a societal perspective and that all costs are 
included regardless of who incurs them.(277) However, ascertaining costs from a societal 
perspective remains challenging. While cost-effectiveness analyses provide a methodology for 
examining the cost of a drug, in the context of the survival benefit, quality of life, cost of drug 
administration, AEs and duration of therapy, they also provide a standard toolkit for measuring 
direct and indirect medical costs. For instance, estimating the unit price of each drug, often uses 
the average wholesale price data.(278) Projections of the costs of managing of AEs can be based 
on published guidelines for resources to be utilized and the costs of resource utilization are 
calculated according to the Medicare physician fee schedule were previously described.(279) This 
methodology can be incorporated into clinical trials or applied retrospectively to completed 
randomized controlled clinical trials as has been done in the evaluations of rituximab maintenance 
therapy and radioimmunotherapy for lymphoma.(233, 234, 237) Such approaches assess the 
financial burden of an intervention in the broader clinical context. These methods should be used 
to examine the general value of a therapy irrespective of the individual patient factors describe 
above that affect and are affected by the financial burden of a therapy. 
The inclusion of patient questionnaires in clinical trials to measure quality of life or other 
patient reported outcome measures is increasing. At the individual patient level, adding 
questionnaires to the evaluation of novel therapies in clinical trials and observational studies that 
measure out-of-pocket costs should be feasible if the correct balance of pertinence and brevity can 
be achieved. Future efforts should draw from expertise in pharmacoeconomics, survivorship, and 
haematological malignancies to tailor existing tools and design questionnaires that objectively 
measure factors that influence a patient’s perception of financial burden such as: debt level, the 
need to borrow money or sell assets to cover healthcare expenses, filings for bankruptcy, and 
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subjective measures concerning perceptions of treatment-related financial burden. In addition, 
questionnaire linking financial burden to patient outcomes are needed. Such tools will enable 
assessment of the impact costly therapies have on treatment adherence, new form of medication 
non-compliance such as dose rationing to reduce the cost of refills, treatment toxicity, treatment 
response, and survival. Ultimately, demonstration of these impacts of financial burden on 
outcomes may motivate efforts to curb the rising costs of treatments for patients with haematologic 
malignancies if in actual practice those treatments do not realize their expected benefits because 
of their financial burden.  
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A Call to Action: Targets & Timelines for Improving Toxicity Assessment in Haematologic 
Malignancies  
 
As a consequence of paradigm shifting changes in disease management approaches in the 
21st century, tremendous progress with improved survival and cure rates in haematologic 
malignancies has been achieved.  However, new therapies, including chronically administered 
targeted agents and immunotherapies, among others, present new challenges.  Patients are living 
with the challenge of managing not just their haematologic malignancy, but also managing chronic 
therapy for their illnesses, with new types of acute, chronic, cumulative and late toxicities that also 
bear potential psychosocial and financial burdens.  This Lancet Haematology Commission 
convened a large, international group of expert authors representing patient advocates, clinicians, 
clinical researchers, regulators, statisticians and methodologists to address challenges in toxicity 
reporting in haematologic malignancies.  This initiative has evaluated current standards of toxicity 
reporting, the need to incorporate patient-reported outcomes, unique issues of toxicity in HCT and 
in survivors of haematologic malignancies, regulatory challenges and implementing real world 
toxicity analysis.  We have identified a range of priority issues for improvement in these topic 
areas, and have proposed immediate- and long- term solutions to these challenges (summarized in 
Table 12). 
Current standard and emerging therapies for haematologic malignancies challenge 
traditional approaches to collecting and communicating drug-related adverse events.  International 
efforts to harmonize systems for patient safety monitoring have been ongoing and need to continue 
to evolve.  The standardization of terminology using consensus definitions such as CTCAE(38) 
remains essential, but it is now also imperative to define adverse events in relation to timing of the 
drug exposure and the duration of these adverse events.  Current methods of AE analysis focusing 
solely on maximum grade tables fall short in describing delayed, chronic or cumulative effects that 
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can limit long-term delivery of therapy.  This issue is particularly relevant with the advent of 
immune therapies and their ensuing irAEs, which can be delayed, unpredictable or prolonged.  
New approaches such as graphical displays from the NCI Web Reporting tool, and longitudinal 
and AUC analyses such as those from the Toxicity over Time(39) have the potential to provide 
more comprehensive toxicity data in numerical and graphical form.  International stakeholder 
consensus on the best metrics and representations is important, with the ultimate goal of 
standardizing requirements for comprehensive, time-dependent toxicity data in publications and 
drug labels.  Additionally, clinical trial design needs to accommodate delayed AEs.  Monitoring 
for dose limiting toxicity should be expanded to two to three cycles prior to establishing a 
recommended phase 2 dosing schedule or expansion cohorts should be encouraged to account for 
delayed AEs in dose determination.   
The changing landscape of therapy for haematologic malignancies requires new methods 
to assess, analyse and interpret cancer drug safety and tolerability internationally which must 
incorporate the voice of the patient via the use of PRO. Clinicians typically tend to underestimate 
the incidence and severity of symptoms compared to patients’ self-reports of similar information 
generated from PRO measures(82).  Clinical trials in patients with haematological malignancies 
do not typically include PRO assessments.  Furthermore, historical PRO tools did not have the 
flexibility to include items that captured differing toxicity profiles seen with the treatments used 
in a specific haematologic malignancy.  Implementing tools to complement clinician-recorded 
CTCAE grading in haematologic malignancy trials, such as the PRO-CTCAE(69), can enhance 
the assessment of tolerability.  Further progress would include better integration and development 
of electronic collection of PROs to enable a patient to report AEs in “real time” through 
smartphones, wearable devices and other technology.  Ideally patient organisations would be 
Final author’s draft of a paper accepted for publication in the Lancet Haematol 12 Jun 18 doi: 
10.1016/S2352-3026(18)30051-6. 
91 
 
involved in the development and validation of these tools. Challenges exist not only in how PRO 
data should optimally be collected but also in how it should be analysed. Lack of consensus as to 
the best analytic approaches for PRO data makes interpretation of the findings and cross-trial 
comparisons challenging. Several international collaborative efforts are underway in key areas 
including identifying core outcome sets, standard PRO analytic methods, and standard PRO 
protocol elements. International consensus on the approaches for use and analysis of PROs with 
clinician graded adverse events needs to be developed across clinical trials, with input from 
cooperative groups, patient organisations, regulatory bodies and agencies. 
Hematopoietic stem cell transplantation presents unique challenges that are related to a 
numerous acute anticipated toxicities, GVHD, drug-drug interactions, infectious AEs, and longer 
term AEs affecting transplant survivors.  The frequency of AEs and their expectedness make 
reporting those that are of relevance an issue in transplantation and other areas of high dose toxic 
therapeutic interventions.  It is essential that the post-HCT AEs be evaluated in the context of 
consensus definitions on what would constitute an “expected” AE depending upon the graft source, 
transplant regimen and other factors. Streamlined approaches are needed to capture and analyse 
these so that unexpected AEs or increases in frequency of expected AEs can be readily detected 
without causing undue burden of reporting to clinicians and research staff.  Automated approaches 
that harness the electronic health record may be helpful in the future.  Given the number of 
interventions, AEs resulting from drug-drug interactions and infectious diseases are very complex 
in transplantation, and their severity is difficult to categorize.  For infectious AEs, scoring 
algorithms must include the number of infectious complications that now occur.  Late term effects 
of transplantation on survivors include infertility, and neurocognitive function, among many 
others, and the understanding of the incidence and character of these delayed effects is currently 
Final author’s draft of a paper accepted for publication in the Lancet Haematol 12 Jun 18 doi: 
10.1016/S2352-3026(18)30051-6. 
92 
 
inadequate.  A more uniform strategy to collect prospective data on fertility and pregnancy 
outcomes, and standardize evaluation and grading of neurocognitive function, as examples, would 
be important tasks for a consensus panel dedicated to improvements in assessment of long term 
AEs in HCT. 
Late and long term toxicities affect many survivors of haematologic malignancies.  
Intrinsic factors (age at diagnosis, sex, inherited genetic susceptibilities) and life style factors 
(smoking, obesity, physical activity, and diet) both impact risks for late toxicity.  Secondary 
malignancies, cardiovascular disease, and psychosocial impairments are major issues that have 
been reported primarily from national or institutional databases. Standardized, international, 
funded, longitudinal patient cohorts of adult survivors of haematologic malignancies are needed 
to collect real life data that cannot come from limited follow up of most clinical trials. Better 
defining non-relapse mortality is essential.  Finding strategies to gather survivors’ health 
information from electronic health records or “big data” repositories is a future avenue. Healthcare 
delivery for survivors beyond surveillance for recurrence also remains a challenge.  Although 
survivorship care plans as a tool have been proposed, implementation into routine practice has not 
been achieved internationally.  Evidence-based guidelines for optimal long-term follow-up care of 
patients with haematologic malignancies, ideally within the context of multidisciplinary dedicated 
survivorship clinics and with the involvement of patient support groups, are needed.  
Making toxicity assessment in haematologic malignancies more comprehensive and 
accurate without adding logistical complexity and burden is a challenge relevant to regulatory 
bodies across the globe(176, 280). Although each country and agency has its own nuanced 
regulatory process, there are many similarities across bodies such as the FDA, EMA, PMDA and 
TGA. Efforts have been made to improve the utility of safety reports and increase the efficiency 
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of reporting process, but there are multiple issues.  Unnecessary safety reports, often the result of 
conservative interpretation of regulatory requirements, are noise that mask true safety signals in 
the reporting system. The risk of missing genuine safety signals due to a large volume of irrelevant 
information is real.  The time and financial resources required for AE reporting are burdensome to 
patients, investigators, nurses and clinical research professionals internationally.  Meanwhile, 
relevant information on drug tolerability, such as drug interruptions, discontinuations, or dose 
reductions are not always accurately reported.  Regulatory agencies have also recognized the need 
to incorporate PRO into tolerability determination, and are involving patient organisations in the 
definition and implementation of pharmacovigilance systems and risk/benefit assessments.  The 
impediments to efficient and informative safety data capture must be discussed at an international 
level, and an expanded toolbox with simplified, uniform electronic submission is needed. Most 
regulatory agencies support data collection in the post-marketing setting as an opportunity to gain 
important additional information on safety and tolerability and revise the package insert of a drug 
if necessary, but these are subject to reporter fatigue and bias – and their existence is also often 
unknown to patients.  Future directions include pursuing opportunities to leverage a variety of real-
world database tools and “big data” resources as novel pipelines of data to improve post-marketing 
toxicity assessment. Further outcomes research to explore ways in which real world data can 
inform product labeling is needed.   
Only a small fraction of patients with cancer are treated on clinical trials. In addition, trial 
populations are often younger or healthier than those with disease in the general population, and 
follow up is limited to detect uncommon or late toxicity.  The use of real world data from patients, 
patient advocacy organizations and databases therefore plays an important role in improving 
toxicity assessment.  Incomplete registrations, inconsistent terminology and documentation, 
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incomplete follow up, biased data and caveats of retrospective causality assessment are all 
substantial limitations of real world data.  Despite these challenges, harnessing registries and 
databases to improve toxicity evaluation portends benefit. Optimizing the systematic, objective 
collection of AE data over multiple time points in real world databases would facilitate the capture 
of clinically significant toxicities in large populations of patients.  This could be practicably carried 
out by focusing on a range of predetermined AEs, certain patient groups, or toxicity categories.  
Learning systems such as the CancerLinQ(187) offer the opportunity to study toxicity in large 
groups of patients by culling data from electronic health records.  Real world AE data is enhanced 
with the direct involvement of patients and patient organisations in the toxicity reporting process.  
Ultimately, one goal would be to develop electronic systems that can capture both physician-
reported and PRO toxicity data in a standardized format for patients being treated off study.  
Consistency in standardization procedures similar to, but perhaps not as rigorous, as those used in 
clinical trials should be applied and further developed.  This unique data would be valuable for the 
characterization of toxicity in non-study patients with haematologic malignancies, and it could 
potentially be harnessed to guide AE management and symptom control in the clinic. 
Adverse effects of haematologic malignancies in real world patients extend beyond 
treatment-related toxicity and include the social and financial effects on the patients and family. 
The financial burden of cancer therapy has become a major social issue internationally, affecting 
patients, providers, health care delivery systems, payers and society(225).  Oral agents such as 
ibrutinib, lenalidomide, venetoclax, and other agents are associated with substantial financial 
burden.  Competition and generic manufacturing drug prices have not altered the course of this 
trend internationally.  Novel approaches to cost-effective care include value-based pricing, 
indication specific pricing and payment by results, among others.  Cost-effective frameworks that 
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address clinical value in the context of cost should be explored, with a goal of ultimately achieving 
consensus on an approach to establishing value in the context of financial impact of drugs of 
haematologic malignancies across multiple international payers.  The complexities go further with 
out-of-pocket cancer care costs, including deductibles, transportation, housing, and other issues.  
These expenses may be associated with refusal of treatment or nonadherence, which can be 
associated with poor clinical outcomes.(275)  At the extreme is financial bankruptcy due to 
treatment-related costs.  Monetary measures, objective measures and subjective measures of the 
financial impact of new cancer therapies.  Each should be assessed in patients treated on 
haematologic malignancy trials and observational studies to better understand financial burden on 
our patients.   
The success in outcomes and survival in many haematological malignancies is historically 
unparalleled and fueled by scientific discovery and implementation.  Measures to address the broad 
facets of toxicity assessment as outlined in Table 12 must be prioritized and further developed to 
ultimately enhance accurate, comprehensive, patient-centered toxicity reporting and inform the 
care of patients with haematologic malignancies.  
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